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ABSTRACT 
 
 
Methicillin-resistant Staphylococcus aureus (MRSA) is an important nosocomial 
pathogen and is also emerging in the community. MRSA is cross-resistant to virtually 
all β-lactam antibiotics and has acquired two main resistance mechanisms: production 
of β-lactamase (bla), coded by blaZ, and production of penicillin binding protein 2a 
(PBP2a), coded by mecA. Both genes are regulated by homologous sensor-transducers 
(BlaR1 and MecR1) and repressors (BlaI and MecI), and coregulation of mecA and blaZ 
by both systems has been demonstrated, although with remarkable different efficiencies. 
In fact, induction of mecA by mecI-mecR1 is so slow that it is believed it is not 
functional in most MRSA strains.  
However, recent data from our laboratory has unexpectedly demonstrated that 
not only there is no correlation between the presence of mecI gene and the resistance 
level in epidemic MRSA strains, but also that for most strains there were no significant 
changes on the resistance phenotype upon the mecI overexpression in trans. 
Interestingly, the two strains in which mecI overexpression affected the resistance 
expression were negative for the bla locus, suggesting that this locus may interfere 
directly with the MecI-mediated repression of mecA and account for those puzzling 
observations.   
In this master thesis we have explored this hypothesis using molecular biology 
strategies and phenotypic analysis of -lactam resistance. The data obtained 
demonstrate that the presence of a wild-type plasmid containing the bla locus not only 
disrupts the MecI-mediated repression, but also significantly enhances the expression of 
resistance. Several preliminary hypotheses were formulated to explain these 
observations and preliminary data, together with published evidence, support the 
working model that BlaI forms functional hetero-dimers with MecI, which upon 
induction are readily inactivated by BlaR1. These results provide new insights into the 
regulatory mechanism(s) of mecA and open new perspectives for the role of β-lactamase 
operon in the MRSA phenotype. 
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RESUMO 
 
 
Os Staphylococcus aureus resistentes à meticilina (MRSA, do inglês 
“methicillin-resistant Staphylococcus aureus”) são um dos principais agentes 
responsáveis por infeções hospitalares. Os MRSA são resistentes a praticamente todos 
os antibióticos β-lactâmicos devido a dois mecanismos principais: produção de β-
lactamase (bla), codificada pelo gene blaZ, e produção de uma proteína de ligação à 
penicilina (PBP2a, do inglês “penicillin binding protein 2”), codificada pelo gene mecA. 
Estes dois genes são regulados por sistemas homólogos, constituídos por um sensor-
transdutor (BlaR1 e MecR1) e um repressor (BlaI e MecI), de tal modo que ambos os 
sistemas são capazes de co-regular os genes mecA e blaZ, embora com eficiências de 
indução muito diferentes. De facto, a indução mediada pelo sistema mecI-mecR1 é tão 
lenta que se acredita que este sistema não está funcional na maioria das estirpes MRSA. 
No entanto, dados recentes do nosso laboratório, demonstram a ausência de 
relação entre a presença do gene mecI e o nível de resistência à meticilina em estirpes 
MRSA epidémicas, e também que, o fenótipo de resistência da grande maioria das 
estirpes não é perturbado pela sobre-expressão em trans do repressor mecI. 
Curiosamente, as duas estirpes em que a expressão da resistência foi afetada pela sobre-
expressão do mecI são negativas para o locus da β-lactamase, o que sugere que este 
locus pode interferir diretamente com a repressão do gene mecA mediada pelo MecI. 
Nesta tese de mestrado esta hipótese foi explorada usando estratégias de biologia 
molecular e ensaios fenotípicos da resistência aos -lactâmicos. Os resultados obtidos 
demonstram que a presença do plasmídeo nativo da β-lactamase não só anula a 
repressão mediada pelo MecI, como também aumenta o nível de resistência das estirpes 
parentais. Várias hipóteses foram então formuladas para explicar estas observações. 
Dados preliminares, em conjunto com evidências experimentais publicadas, sugerem 
que o BlaI forma hetero-dímeros com o MecI que, após a indução, são inativados 
eficientemente pelo BlaR1. Em conclusão, estes resultados apresentam novas 
perspetivas para o mecanismo de regulação do mecA e para uma  nova importante 
função do operão da β-lactamase para o fenótipo das estirpes MRSA. 
 
TABLE OF CONTENTS 
_____________________________________________________________________________________ 
v 
 
TABLE OF CONTENTS                                                                                        
 
 
ACKNOWLEDGMENTS ................................................................................................ ii 
ABSTRACT ..................................................................................................................... iii 
RESUMO ......................................................................................................................... iv 
ABBREVIATIONS ........................................................................................................ vii 
LIST OF TABLES ........................................................................................................... ix 
LIST OF FIGURES ......................................................................................................... xi 
INTRODUCTION ............................................................................................................ 1 
1. The Staphylococcus genus ......................................................................................... 1 
2. Staphylococcus aureus as a human pathogen ............................................................ 1 
2.1 Clinical relevance ............................................................................................... 1 
2.2 Virulence factors ................................................................................................ 2 
2.3 Antibiotic resistance ........................................................................................... 3 
2.4 Epidemiology of antibiotic resistance ................................................................ 3 
2.5 Treatment and prevention .................................................................................. 5 
3. β-lactam resistance mechanisms................................................................................ 6 
3.1 Cell wall: the β-lactams target............................................................................ 6 
3.2 Penicillin resistance ............................................................................................ 7 
3.2.1 β-lactamase ................................................................................................. 7 
3.2.2 β-lactamase operon ..................................................................................... 8 
3.3 Methicillin-Resistant Staphylococcus aureus (MRSA) ................................... 10 
3.3.1 mecA gene ................................................................................................. 10 
3.3.2 SCCmec .................................................................................................... 10 
3.3.3 Heterogeneous and homogeneous resistance ............................................ 11 
3.3.4 Origin and evolution ................................................................................. 12 
3.3.5 Molecular epidemiology of MRSA .......................................................... 13 
4. Regulation of β-lactam resistance ........................................................................... 14 
5. Role of β-lactamase operon in the stabilization and expression of methicillin 
resistance in S. aureus ............................................................................................. 17 
MATERIALS AND METHODS .................................................................................... 20 
TABLE OF CONTENTS 
_____________________________________________________________________________________ 
vi 
 
1. Bacterial strains and plasmids ................................................................................. 20 
2. Molecular methods .................................................................................................. 23 
2.1 DNA isolation .................................................................................................. 23 
2.2 DNA purification and manipulation ................................................................. 24 
2.3 Electrophoresis analysis of PCR and DNA restriction reactions ..................... 24 
2.4 Electroporation of recombinant plasmids into S. aureus ................................. 25 
3. Overexpression of β-lactamase regulatory genes .................................................... 26 
4. Genetic knock-out of β-lactamase regulatory genes ............................................... 27 
5. Phenotypic analysis ................................................................................................. 29 
RESULTS ....................................................................................................................... 31 
1. Introduction of native β-lactamase plasmid into prototype strains ......................... 31 
1.1 Introduction of native β-lactamase plasmid into strain COL-I ........................ 31 
1.2 Introduction of native β-lactamase plasmid into VNG17 and VNG17-I strains
 ………………………………………………………………………………...33 
1.3 Introduction of native β-lactamase plasmid into RJP17 and RJP17-I strains .. 35 
1.4 Introduction of native β-lactamase plasmid into HT0350 strain ...................... 36 
2. Phenotypic effect of clavulanic acid ........................................................................ 38 
3. Introduction of β-lactamase regulators into COL-I strain ....................................... 40 
3.1 Introduction of blaIblaR1 into COL-I strain .................................................... 40 
3.2 Introduction of blaR1 and blaI genes into COL-I strain .................................. 40 
3.3 Introduction of blaR1 domains into COL-I strain ............................................ 41 
4. Deletion of bla regulators from native β-lactamase plasmid ................................... 43 
DISCUSSION AND CONCLUSION ............................................................................ 44 
REFERENCES ............................................................................................................... 52 
ANNEX .......................................................................................................................... 64 
 
 
 
 
 
 
ABBREVIATIONS 
_____________________________________________________________________________________ 
vii 
 
ABBREVIATIONS  
 
 
Amp: Ampicillin 
ATc: Anidrotetracycline 
 
bla: β-lactamase 
bp: Base pairs 
 
CA: Clavulanic acid 
CA-MRSA: Community acquired methicillin-resistant Staphylococcus aureus 
CC: Clonal complex 
Cd: Cadmium 
Cf: Final concentration 
Cm: Chloramphenicol 
 
dNTP’s: Desoxiribonucleotides 
 
GlcNAc: N-acetylglucosamine 
 
IPTG: Isopropyl β-D-1-thiogalactopyranoside 
IS: Insertion sequence 
 
kb: Kilobase 
 
LA: Luria-Bertani agar 
LB: Luria-Bertani broth 
ABBREVIATIONS 
_____________________________________________________________________________________ 
viii 
 
 
MIC: Minimum inhibitory concentration 
MLST: Multilocus sequence typing  
MRSA: Methicillin-resistant Staphylococcus aureus 
MSSA: Methicillin-susceptible Staphylococcus aureus  
MurNAc: N-acetylmuramic acid 
  
Oxa: Oxacillin 
 
PBP: Penicillin binding protein 
PCR: Polymerase chain reaction 
Pen: Penicillin 
PFGE: Pulse field gel electrophoresis 
 
SCCmec: Staphylococcal cassette chromosome mec  
spaA: Staphylococcus aureus protein A 
ST: Sequence type 
 
Tc: Tetracycline 
TSA: Triptic soy agar  
TSB: Triptic soy broth  
 
Vf : Final Volume 
VISA: Vancomycin-intermediate Staphylococcus aureus 
VRSA: Vancomycin-resistant Staphylococcus aureus 
 
LIST OF TABLES 
_____________________________________________________________________________________ 
ix 
 
LIST OF TABLES 
 
 
Table 1 – Strains and plasmids………………………………………………………... 20 
 
Table 2 – Oxacillin-resistance of parental strain COL and recombinant strains……... 32 
 
Table 3 – Oxacillin-resistance of parental strain VNG17 and recombinant strains…... 34 
 
Table 4 – Oxacillin-resistance of parental strain RJP17 and recombinant strains……. 36 
 
Table 5 – Oxacillin-resistance of parental strain HT0350 and recombinant strains….. 37 
 
Table 6 – Clavulanic acid effect on oxacillin and penicillin-resistance phenotype…... 39 
 
Table 7 – Oxacillin-resistance of strain COL transformed with β-lactamase regulators 
…………………………………………………………………………………………. 42  
 
Table 8 – Culture media….…………………………………………………………… 64 
 
Table 9 – Buffer solutions……………………………………………………………. 64 
 
Table 10 – Media and solutions for transduction experiments……………………….. 65 
 
Table 11 – Cell-wall lysis enzymes…………………………………………………… 65 
 
Table 12 – Antibiotic solutions……………………………………………………….. 66 
 
Table 13 – Restriction endonucleases………………………………………………… 66 
 
Table 14 – List of primers…………………………………………………………….. 67 
 
 
LIST OF TABLES 
_____________________________________________________________________________________ 
x 
 
Table 15 – Routine PCR reaction mix……………………….……………………….. 68 
 
Table 16 – High-fidelity PCR mix……………………………………………………. 68 
 
Table 17 – Thermocycling conditions………………………………………………… 69 
 
Table 18 – Summary of experimental phenotypic data……………….………………. 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF FIGURES 
_____________________________________________________________________________________ 
xi 
 
LIST OF FIGURES 
 
 
Figure 1 – Timeline of the four resistance waves in S. aureus……………………….. 4 
 
Figure 2 – Structure of Penicillin and Methicillin……………………………………..7 
 
Figure 3 – β-lactamase operon………………………………………………………... 9 
 
Figure 4 – Regulation of β-lactam resistance…………………………………………. 16 
 
Figure 5 – Map of pKOR1……………………………………………………………. 28 
 
Figure 6 – Phenotypic expression of oxacillin resistance in COL and recombinant 
strains………………………………………………………………………………….. 32 
 
Figure 7 – Phenotypic expression of oxacillin resistance in VNG17 and recombinant 
strains………………………………………………………………………………….. 34 
 
Figure 8 – Phenotypic expression of oxacillin resistance in RJP17 and recombinant 
strains………………………………………………………………………………….. 35 
 
Figure 9 – Phenotypic expression of oxacillin resistance in HT0350 and recombinant 
strains………………………………………………………………………………….. 37 
 
Figure 10 –Membrane topology of the penicillin-sensory transducer BlaR1 ………...49 
 
Figure 11 – β-lactamase operon and cloning fragments……………………………… 70 
 
 
INTRODUCTION 
_____________________________________________________________________________ 
1 
 
INTRODUCTION 
 
 
1. The Staphylococcus genus 
 
Staphylococci are gram positive cocci of about 0,8-1,0 µm in diameter that 
divide in perpendicular planes to form irregular clumps. They are facultative anaerobes, 
nonsporulating, but are resistant to drying and are readily dispersed in dust particles 
through the air and surfaces (77, 105). 
Staphylococcus genus belongs to Staphylococcaceae family and so far 45 
species and 24 subspecies have been identified (38). The genus contains common 
pathogens of humans and animals and commonly infects the skin and wounds, 
occasionally causing life-threatening diseases (92). In humans two major species are 
recognized, Staphylococcus epidermidis, a nonpigmented, comensal, nonpathogenic 
organism usually found on the skin or mucous membranes and Staphylococcus aureus, 
a yellow pigmented species that is often associated with pathological conditions (96). 
 
 
2. Staphylococcus aureus as a human pathogen 
 
2.1 Clinical relevance 
 
Staphylococcus aureus is the leading cause of nosocomial infections ranging 
from minor skin diseases to severe infections, as endocarditis and septicemia (2). The 
primary reservoir for S. aureus is the nasal cavity and three carriage patterns have been 
proposed: persistent, intermittent and noncarriage (146). Based on surveillance studies, 
in the United States of America, the United Kingdom, Japan, and other countries, it is 
estimated that at any time one third of the population is colonized with S. aureus 
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asymptomatically (148). The nasal carriage can be a risk factor for endogenous 
infection as these commensal bacteria have the ability to disseminate and invade the 
host organism (111) but, normally, these individuals do not acquire disease, presumably 
because the other resident microorganisms compete successfully for resources and limit 
pathogen growth. In addition, in healthy individuals the innate immune system is 
particularly active at mucosal surfaces and may inhibit the microbial growth. Most 
infections result from a colonized individual that transmits to a weakened individual or 
infects a damaged tissue (25). The most common infections, impetigo, cellulitis and 
abscesses are the result of invasion and laceration of the skin or cellular tissues. The 
dissemination to adjacent tissues can originate bacteremia, endocarditis, osteomyelitis, 
arthritis and pneumonia. S. aureus infections are also associated with the presence of 
medical devices in the organism (78). 
 
 
2.2 Virulence factors 
 
The virulence of S. aureus is due to a combination of many virulent factors such 
as toxins, enzymes, cell wall components and antigens (92). S. aureus secrete several 
toxins responsible for different symptomatologies as food poisoning (enterotoxins A, B, 
C, D, E, G and H), scalded skin syndrome (exfoliating toxin A and B) and toxic shock 
syndrome (enterotoxin TSST-1). These toxins can work as superantigens stimulating 
large numbers of immune response cells, resulting in extended inflammatory reactions 
(91). 
Along with toxins this bacteria secretes hemolisins (α, β, γ and δ), a leucocidin 
and a few enzymes (coagulase, hialurodinase, fibrinolisine, catalase, lipase and 
nucleases) that contribute to damage the host cell or stimulate a large number of 
lymphocytes and cause systemic inflammatory responses (32). The fibrin matrix 
produced as a result of coagulase activity protects the bacteria from attack by host cells 
and probably accounts for the extremely localized nature of many S. aureus infections 
as in boils and pimples (148, 150). This enzyme enables differentiation of S. aureus 
from many other staphylococcal species (26). 
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2.3 Antibiotic resistance 
 
Antibiotic resistance is associated with the permanent change of the highly 
flexible bacterial genome under pressure (43). In fact, although Staphylococcus aureus 
is naturally susceptible to virtually every antibiotic developed so far (18), it is one of the 
pathogens of greatest concern because of its incredible facility to acquire antibiotic 
resistance traits along with the ability to cause life-threatening infections and to adapt to 
different conditions (89). Although chromosomal mutations are also important, 
resistance is often a consequence of horizontal gene transfer, mostly occurring in 
hospitals and healthcare institutions, where the selective pressures for resistance are 
greatest (27, 94).  
As new antibiotics have emerged, such as, quinolones, aminoglycosides, 
oxalidiones, S. aureus has developed efficient mechanisms to neutralize them (88). But 
the increasing overall burden of staphylococcal disease in many countries in both 
healthcare and community settings is mainly caused by methicillin-resistant S. aureus 
strains (MRSA), which are virtually resistant to all classes of β-lactams (44). Infections 
caused by antibiotic-resistant strains of S. aureus have reached epidemic proportions in 
many parts of the world and resistant strains that are contained within hospitals 
temporarily, can eventually arise within the community (52). 
 
 
2.4 Epidemiology of antibiotic resistance 
 
Before the discovery of β-lactams the mortality rate of S. aureus invasive 
infection was about 80% (88). Introduction of penicillin into clinical practice, in 1940, 
allowed a drastic decrease in the mortality rate (103, 135). However, penicillin 
resistance has developed soon after as a natural evolutionary response of bacteria to this 
drug (30, 75). To combat penicillin-resistant strains, methicillin was introduced into 
clinical practice, in 1960. However, in 1961, the first MRSA strains were described (8). 
Over the years, new successful clones have arisen, giving rise to the on-going 
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worldwide pandemic of MRSA in hospitals, although the prevalence of infections may 
vary significantly in different countries (49, 136) (Fig. 1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In response to β-lactams, S. aureus has acquired two main resistance 
mechanisms: production of β-lactamase, that hydrolyze the β-lactam ring of penicillin, 
and production of PBP2a, an extra penicillin binding protein (PBP) with low affinity to 
virtually all β-lactams (60, 95). This latter mechanism, characteristic of MRSA, together 
with the former, confers resistance to all β-lactams, including penicillins, 
cephalosporins and carbapenems. The β-lactam resistance genes were spread over time 
duo to horizontal transfer and clonal expansion in several waves (18). 
Figure 1 - Timeline of the four resistance waves in S. aureus 
(18). Wave 1 began after the introduction of penicillin into clinical 
practice and continues till today. Wave 2 had arisen after the 
introduction of methicillin into clinical practice (first MRSA 
strains). Wave 3 began with emergence of new MRSA strains, 
marking the on-going worldwide pandemic of MRSA. Wave 4 
began with the emergence of MRSA strains in the community.  
INTRODUCTION 
_____________________________________________________________________________ 
5 
 
Traditionally, MRSA strains have been recognized mainly as nosocomial 
pathogens. However, in recent years, its epidemiology has radically changed, being 
increasingly isolated in the community and affecting people without known risk factors 
(52). The first cases of community-acquired MRSA (CA-MRSA) infections were 
reported in indigenous populations in Australia, in the early 1990’s (144), and soon after 
in the United States (113), which were followed by several reports worldwide (15, 123). 
Unlike hospital clones, CA-MRSA’s were susceptible to most antibiotics but contained 
several virulence factors (22, 61, 106).  
Most contemporary MRSA strains are resistant to many classes of antimicrobial 
agents leaving physicians with few therapeutic options. Glycopeptides are considered 
the last resort therapy against MRSA (76). However, in 1997, the first case of reduced 
susceptibility to vancomycin, designated VISA from vancomycin-intermediate 
Staphylococcus aureus, was described (63). Since then, several MRSA strains with 
reduced susceptibility to vancomycin have been found throughout the world (93, 133, 
134). In 2002, for the first time, a strain fully resistant to vancomycin was identified, 
designated VRSA from vancomycin-resistant Staphylococcus aureus (33). In contrast to 
the chromosomally mediated resistance for VISA strains that result in a thickened cell 
wall (54, 55), the VRSA strains acquired the vanA operon from Enterococcus faecalis, 
which allows synthesis of the terminal peptide ended in D-Ala-D-Lac, rather than D-
Ala-D-Ala. This new terminus has a remarkable reduced affinity for vancomycin (48, 
129). Together with CA-MRSA, VISA and VRSA are the most recent waves of 
antimicrobial resistance in S. aureus (18). 
 
                    
2.5 Treatment and prevention 
 
Extensive use of antibiotics has promoted the selection of resistant 
Staphylococcus aureus strains and, as a result, the therapeutic options are often scarce 
(34, 88). Prevention of staphylococcal infections is problematic because many 
individuals are asymptomatic carriers, and diseases such as acne and impetigo can be 
transmitted by simple contact with contaminated hands. To control this transmission in 
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surgery wards and nurseries the carriers of known pathogenic strains must be isolated or 
treated to eradicate the carrier state (35, 101). Nowadays, the treatment of choice for S. 
aureus infection in most countries is a penicillin-resistant β-lactam antibiotic (for 
example, oxacillin or cloxacillin) or a lipopeptide (daptomycin) (9, 127). Combination 
therapy with gentamicin may be used to treat serious infections like endocarditis, but its 
use is controversial because of the high risk of damage to the kidneys (23). 
 
 
3. β-lactam resistance mechanisms 
 
3.1 Cell wall: the β-lactams target 
 
In gram positive bacteria the peptidoglycan is the main constituent of cell wall. 
It is a polymer with a complex organization that confers mechanic resistance to the cell 
(125). The basic unit of the peptidoglycan is a disaccharide-pentapeptide composed of 
the amino sugars N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), 
which are linked together by β-1,4 glycosidic bonds. In S. aureus each MurNAc is 
attached to a short amino acid chain that can be cross-linked to an amino acid chain of 
another strand through a pentaglycine, allowing the formation of peptide cross bridges 
(126). The polymerization of the newly synthesized disaccharide-peptide and 
incorporation into the growing peptidoglycan are achieved through the action of four 
penicillin-binding proteins (PBP1, PBP2, PBP3 and PBP4), which catalyze the 
transpeptidation and transglycosylation reactions responsible for the formation of the 
peptidic and glycosidic bonds, respectively (47, 124, 132).    
β-lactams inhibit the cell wall synthesis (Fig. 2). All β-lactams have in common 
a β-lactam ring, which has a similar structure to the natural substrate of PBP’s, the D-
Ala-D-Ala terminus of the amino acid chain. Thus, the β-lactam competes with the 
natural substrate for the active site of these enzymes, preventing the final stages of 
peptidoglycan synthesis. This process causes primarily a cell growth arrest and 
ultimately autolysis and cell death (90). Notably, this class of antimicrobial agents 
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stands up in clinical practice due to the low toxicity in eukaryotic organisms, since they 
act in an exclusively bacterial structure (145). 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Penicillin resistance 
 
3.2.1 β-lactamase 
 
In bacteria, four types of β-lactamases (A, B, C, D) have been distinguished by 
serotyping and differences in hydrolysis rates of selected β-lactam substrates (74). 
Types A, C and D are usually located on plasmids and are active-site serine enzymes, 
whereas type B enzymes typically reside in the chromosome and are zinc-dependent 
(97, 147). Structural evidences support the proposal that β-lactamases descended from 
the cell wall PBP’s (97). The action of this group of enzymes consists on the interaction 
with the β-lactam antibiotic and subsequent disruption of the amide bond in the four-
membered β-lactam ring, rendering the antibiotic inactive in an irreversibly manner (19, 
86, 153). 
Figure 2 - Structure of Penicillin (A) and Methicillin (B). 
A. B. 
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Staphylococcal β-lactamases are from type A (115) and are large surface 
attached molecules that reduce the external level of active drug. Penicillin-resistant 
strains have acquired an exogenous plasmid coding for penicillinase, which confers 
resistance only to penicillin (86). When penicillin was introduced into clinical practice, 
only about 5% of S. aureus isolates acquired the plasmid but, since then, through 
horizontal transfer of the plasmid and strain selection, 80 to 90% of isolates carry the -
lactamase gene (82, 85, 86).  
 
3.2.2 β-lactamase operon 
 
In S. aureus the operon responsible for synthesis of β-lactamase is located in 
transposon Tn552 (117) and contains the blaZ gene, which encodes for β-lactamase, and 
the regulatory genes blaR1 and blaI (4, 139). These regulatory genes are divergently 
transcribed from blaZ (20) (Fig. 3).  
BlaR1 is a high molecular weight sensor-transducer transmembrane protein and 
consists of two domains (97). One is a carboxyl-terminal domain of approximately 27-
kDa, the sensor domain, extending to the extracellular medium and containing penicillin 
binding motifs, that have been shown to bind to β-lactam compounds, and an active site 
serine, which is involved in activation of the signaling cascade (73, 151). The other 
domain is an amino-terminal domain of approximately 38 kDa, the transducer, that is 
intracellular and contains four transmembrane α-helices (TM1, TM2, TM3, TMA4) 
(57). These transmembrane segments are interconnected by three loops (L1, L2, L3), 
where L1 and L3 connect to cytoplasm and L2 is exposed on the outside of the cell. The 
L3 segment has a zinc metalloprotease domain, defined by a histidine sequence and a 
glutamic acid, which is believed to interact in an unknown way with promoter-bound 
BlaI dimers (56, 155).  
BlaI is a repressor that blocks transcription of both structural and regulatory 
genes and has been shown to bind specifically to two regions of dyad symmetry, the 
operators, which are located between blaZ and the regulator blaR1 (R1 dyad and Z 
dyad) (20, 51). A dimeric BlaI, binds non cooperatively but with similar affinities to the 
two operators resulting in repression of blaZ along with the regulators (50). This 
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repressor has two functional domains. The amino-terminal domain of approximately 11 
kDa is responsible for operator recognition, and the carboxyl-terminal domain of 
approximately 3 kDa for subunit dimerization (50). DNA-binding experiments 
demonstrate that formation of BlaI dimer, as well as intact amino and carboxyl termini, 
are absolutely required for the binding activity of the protein (20, 152). Proteolytic 
cleavage disrupts the dimer interface, causing its dissociation and releasing from the 
operator (155). In 1968, Cohen and Sweeney have speculated on the existence of 
another regulator, the chromosomal gene blaR2, involved in the induction of β-
lactamase (21). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3 - β-lactamase operon (87). 
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3.3 Methicillin-Resistant Staphylococcus aureus (MRSA) 
 
3.3.1 mecA gene 
 
 
The characteristic element of all methicillin-resistant S. aureus (MRSA) strains 
is a specific gene, mecA, which codes for PBP2a, an inducible 76 kDa PBP that is 
absent in susceptible strains (14, 60). In MRSA, PBP2a, which has low binding affinity 
to β-lactam antibiotics, can substitute for essential functions of high affinity PBP’s and 
enables staphylococci to survive under exposure to high concentrations of these agents 
(60, 112). The organization of the mec operon is similar to the bla operon, containing 
the mecA gene and the respective regulators, mecI and mecR1 (62). In fact, bla and mec 
regulatory genes have been shown to be interchangeable in vivo (83, 99). 
Although clearly necessary, there are some evidences suggesting that mecA may 
not be sufficient to assure high-level resistance to methicillin. As a matter of fact, it has 
been shown that MRSA strains with virtually identical amounts of PBP2a, showed 
methicillin inhibitory concentrations (MIC) values spread over a range of several 
hundred fold (59, 119). Later it was demonstrated the importance of many chromosomal 
genes in defining resistance levels, namely the fem genes (for factor essential for 
methicillin resistance), that do not interfere with the transcription and transduction of 
mecA (10, 11). De Lencastre et al. proposed that the survival and growth of these 
bacteria in the presence of β-lactams require the cooperative functioning of a large 
number of genes, a process similar to the bacterial stress response mechanism (28). 
 
 
3.3.2 SCCmec 
 
The mecA gene is incorporated into a large mobile genetic element, the 
staphylococcal cassette chromosome mec (SCCmec) (66). The emergence of MRSA 
lineages is due to the acquisition and insertion of SCCmec element into a chromosome 
gene of unknown function, the orfX gene, by susceptible strains (29, 68). SCCmec 
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contains the mec gene complex, which includes mecA and the regulatory genes mecI 
and mecR1, and the ccr gene complex, which encodes for recombinases that allow 
mobility of SCCmec (68). Besides these gene complexes, there are also three so-called 
J-regions (J1, J2 and J3), which constitute non-essential components of the cassette and 
may carry additional antimicrobial resistance determinants (65, 66).  
SCCmec elements are highly diverse in their structural organization and genetic 
content (37) and have been classified into types and subtypes. Types are defined by the 
combination of the ccr gene complex allotype and the class of mec gene complex. 
Variations in the J regions within the same mec-ccr complex are used for defining 
subtypes. To date, eight major SCCmec types, designated I to VIII, have been 
recognized along with numerous subtypes (29, 68) and three new types, IX to XI, have 
been recently described (84, 131). 
There are three classes for the mec gene complex in S. aureus. The class A mec 
gene complex, the prototype complex, contains intact mecA, mecR1 and mecI, a 
hypervariable region (HVR) and insertion sequence (IS) IS431. The class B mec gene 
complex is composed of intact mecA, a truncated mecR1 (N-terminal inducer domain 
only) that resulted from insertion of IS1272, a HVR and the same IS as class A. The 
class C mec is similar to class B but mecR1 gene is truncated by IS431 (first 111 bp 
only) and is subdivided in two sub classes depending on the orientation of the IS’s. The 
ccr complex consists of two adjacent genes, ccrA and ccrB, in SCCmec I-IV, VI and 
VIII, and ccrC in V and VII (65, 68). 
 
3.3.3 Heterogeneous and homogeneous resistance 
 
The phenotypic expression of methicillin resistance is highly dependent on 
growth conditions such as, temperature, medium salt concentration, growth phase and 
other external factors (128). In addition, many MRSA strains exhibit a heterogeneous 
expression profile, in which the majority of cells are susceptible to low concentrations 
of β-lactam antibiotic, with only a small proportion growing at high concentrations 
(119). Growth of a heterogeneous strain in the presence of β-lactam antibiotic alters the 
resistance phenotype by selecting for highly resistance clones. These clones produce a 
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homogeneous population of highly resistant cells that can grow at high concentration of 
antibiotic (59). In laboratory, with repeated subculture in antibiotic-free medium, the 
proportion of highly resistant cells gradually diminishes and the original heterogeneous 
pattern reemerges in most strains (141). There are some rare clinical isolates that 
consistently are homogeneous despite repeated subculture, with the COL strain of S. 
aureus being one of these (16, 59). 
The phenomenon of heterogeneous and homogeneous resistance in wild-type 
strains is still unexplained. Heterogeneous strains may be deficient in a factor or lack a 
critical modification in a biochemical pathway, possibly for cell wall synthesis, that is 
important for functions of PBP2a. Homogeneous strains then arise from heterogeneous 
strains by antibiotic selective pressure favoring clones whose genetic background is 
well adapted for a fully functional PBP2a (16, 138).  
In the clinical setting, the heterogeneous phenotypic expression of oxacillin 
resistance is a major problem, since it may originate false negatives in the phenotypic 
detection assays of resistance. Because these strains are in fact positive for mecA, 
prescription of β-lactam antibiotics may select for high-level β-lactam resistant MRSA 
subpopulations, causing treatment failures (42, 64). 
Another type of methicillin resistance is the borderline (or low-level) resistance, 
exhibited by strains with a minimum inhibitory concentration (MIC) at or just above the 
susceptibility breakpoint (17, 102). Borderline strains can be divided in two types: 
strains with mecA gene and production of PBP2a, presenting a heterogeneous profile, 
and strains without mecA gene, which do not contain highly resistant subpopulations. 
These mecA-negative strains can result from modification of normal PBP genes or 
overproduction of staphylococcal β-lactamase (140). As this later mechanism led to 
low-level resistance it is not as clinically relevant as production of PBP2a (140). 
 
3.3.4 Origin and evolution 
 
 In the search for the possible origin of mecA, some authors identified a genetic 
element closely related to the S. aureus mecA gene in the animal commensal species 
Staphylococcus sciuri (24). This element is the pbpD gene, which is the genetic 
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determinant of penicillin binding protein 4 (PBP4) of S. sciuri that was shown to share 
several properties with S. aureus PBP2a (1). However, this homologue was not 
identified as part of the mec gene complex or of the SCCmec element. In 2010 
Tsubakishita et al. observed a potential mechanism of the generation of a new SCCmec-
like element in Macrococcus caseolyticus (143), and, more recently, a divergent mecA 
homologue was discovered in human and bovine populations located in a novel 
staphylococcal cassette chromosome mec element (SCCmec type-XI) (45). 
 
3.3.5 Molecular epidemiology of MRSA 
 
Currently, the characterization of methicillin-susceptible Staphylococcus aureus 
(MSSA) and MRSA clones is mostly based on three molecular methods. 
 Pulse field gel electrophoresis (PFGE) is a technique based on the resolution of 
large restriction fragments in an agarose gel, resulting from the digestion of total DNA 
with a rare cutter enzyme (e.g. SmaI) (98). The groups defined by PFGE are clustered 
into types, with a similarity coefficient of 80%, and subtypes, with a similarity 
coefficient of 95% (39). 
Multilocus sequence typing (MLST) is a genotyping method based on sequence 
analysis of approximately 450 base pairs (bp) of seven housekeeping genes. Isolates 
with identical sequences at the seven genetic loci are grouped in the same sequence type 
(ST). S. aureus isolates that differ in less than three loci are assigned into the same 
clonal complex (CC) (36, 40). 
Spa typing is a method designed for investigation of S. aureus outbreaks and 
relies upon analysis of variable numbers of tandem repeats in spa gene, which codes for 
protein A, a constituent of the cell wall. This method takes into account the number of 
repeats as well as point mutations (130). 
Molecular typing of large international strain collections using these techniques 
has shown that 88% of the MSSA strains can be assigned to one of eleven clonal 
complexes, whereas MRSA strains are generally concentrated into one of six. This 
means that MSSA strains have a more diverse genetic structure and this is in agreement 
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with the hypothesis that MRSA derived recently from a limited number of MSSA 
lineages by acquisition of SCCmec (39, 66).      
 
 
4. Regulation of β-lactam resistance 
 
 
The signaling pathway that regulates β-lactam resistance has been studied for 
many years. Although β-lactamase and PBP2a are genetically and biochemically 
diverse, they are both dependent on a series of proteolytic cleavages of signaling 
components and are regulated by similar proteins (155). When a β-lactam antibiotic 
binds to the sensor domain of BlaR1 it reacts with the serine active site causing serine 
acylation, which is presumable, the initial event (151). Recently, it was hypothesized 
that signal propagation is mediated by an altered interaction between the BlaR1 sensor 
domain and the L2 extracellular loop, which might induce a conformational change in 
the transducer domain, leading to activation of the zinc-metalloprotease through a series 
of proteolytic steps (56, 57). Zhang et al proposed an autocatalytic cleavage of the 
transducer domain of BlaR1, metalloprotease dependent, which promotes, directly or 
indirectly, cleavage of the dimeric BlaI (155). Probably, other molecules are also 
required because it has not yet been demonstrated a direct association between the 
sensor-transducer and the repressor (3). The BlaI cleavage occurs near the carboxyl 
terminal and generates an 11-kDa and a 3-kDa fragment (155). C-terminal cleavage 
renders the repressor unable to dimerize, a necessary condition for repressor activity. 
Thus, proteolytic cleavage causes dimer dissociation and consequently, its releasing 
from DNA (87). However, the induction process does not promotes a completely 
cleavage of the repressor, and about 40-50 % of the intact dimer is still present (155). 
Fileé et al suggested the presence of a ligand acting as a co-activator that could displace 
the repressor from its respective operator, inducing a conformational change in the 
repressor. Thus, the BlaI proteolysis might be a secondary phenomenon resulting from 
the activity of cellular proteases (41). Following proteolysis, BlaI dissociates from its 
divergon binding site, enabling transcription of blaZ, blaR1 and blaI, and, consequently 
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production of β-lactamase and the respective regulators (50). When BlaR1 is cleaved it 
can no longer be functional (12). Thus, this protein must be continually produced in 
order to sense the β-lactam and keep the signal-transduction active. This explains why 
BlaR1 production is linked with β-lactamase production (155). When the extracellular 
antibiotic concentration decreases, BlaR1 is no longer auto-activated, and in 
consequence the BlaI proteolytic cleavage stops. The repressors gain conditions to 
dimerize again and to bind DNA, suppressing blaZ, blaR1 and blaI expression (99, 
155).  
This regulatory system is unique among bacteria. In fact, a signal transmitted by 
proteolytic events had not been described among these microorganisms so far (3, 155). 
Among the unknown questions concerning this signaling transduction pathway are the 
mechanism of BlaR1 acylation, the proteolytic cleavage events and the repressor 
mechanisms once the threat of the β-lactams has passed (43). 
Expression of mecA is believed to be regulated by a similar pathway, with the 
respective regulators, the sensor-transducer, MecR1, and the repressor, MecI (3) (Fig. 
4). Interestingly, the two repressors are virtually interchangeable, which is a 
consequence of their similarity (99). BlaI and MecI are almost identical, sharing 60% of 
amino acid identity and the proteolytic cleavage takes place at the same two amino 
acids in the same position (46). In fact, there is a cross-talk between both regulatory 
systems, which means that both can control the transcription of blaZ and mecA (53, 83, 
99). However, this homology does not extend to the sensor-traducers, BlaR1 and 
MecR1, which share 34% amino acid identity only, and as such are not interchangeable 
(99). 
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The main difference between these two systems is the kinetics of the signal-
transduction. BlaR1 takes only a few minutes to induce blaZ/mecA expression, whereas 
MecR1 takes several hours (53, 99, 118). This might happen because MecI is a much 
stronger repressor than BlaI or because the poor response of MecR1 to some penicillins, 
such as methicillin and oxacillin (10). Moreover, the putative chromosomal encoded 
factor, BlaR2 may have a role in BlaI cleavage (21, 121). Actually, due to this slow 
induction most contemporary MRSA strains had lost or have mutations in the mec 
regulatory genes (138). Others, called pre-MRSA, that carry mecA and fully functional 
mecI and mecR1 genes are, in clinical terms, phenotypically susceptible to methicillin, 
precisely due to the strong repression of MecI (81). Some studies that corroborate this 
observation showed that, the in vitro deletion of mecI caused the increase in the 
resistance levels of β-lactams (31, 81). In fact, in 1992, Hiramatsu et al stated that the 
high level of resistance to β-lactam antibiotics acquired by MRSA was explained by 
some genetic alterations in the regulatory genes mecR1 and mecI (81, 138). 
Figure 4 - Regulation of β-lactam resistance in S. aureus (3). 
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Interestingly, the great majority of clinical MRSA strains is positive for the β-lactamase 
locus (86). Therefore, in clinical isolates, the regulation of PBP2a is accomplished 
mainly by bla regulatory genes because of deletions and mutations in the mec regulatory 
genes (72). All these facts lead to the proposal of the current model for the 
transcriptional expression of mecA in contemporary MRSA strains: high-level resistance 
to β-lactams, implies non-functional mecI-mecR1 regulatory system, and, strains 
possessing wild type regulatory genes present low resistance to β-lactams (81). Despite 
this fact, other studies have shown no correlation between the presence of MecI and the 
MIC level, as some strains negative for mec regulatory genes have a low resistance 
level, while other strains with intact locus are highly resistant (61, 103). Furthermore, 
two major pandemic nosocomial MRSA clones have a complete mecI-mecR1 locus, 
suggesting no correlation between the epidemicity of MRSA and regulators 
functionality (37, 109). Based on these contradictory observations, it has been 
postulated the existence of other unknown determinants controlling the mecA 
expression (79, 149).  
 
 
 
5. Role of β-lactamase operon in the stabilization and expression of 
methicillin resistance in S. aureus 
 
 
The restricted distribution of the SCCmec element within S. aureus population 
may be partly determined by strain properties that contribute to transformation 
efficiency and the stability of PBP2a, suggesting that some genetic backgrounds are 
better adapted than others to SCCmec and mecA acquisition (72). Chambers et al. 
observed that the major MRSA lineages might be favored recipients while MSSA 
strains can only tolerate mecA to some extent. This factor could account for the 
relatively limited clonal distribution of mecA in nature in addition to the fitness cost 
associated to SCCmec and the low antibiotic selective pressure (71). 
 Regulatory genes seem to have an important permissive role that allows a 
restrictive host genome to become transformed by mecA (13). Particularly interesting is 
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the ability of mec or bla regulatory genes to stabilize mecA, a finding that suggests a 
role of these elements in facilitating the dissemination of this gene. As mecR1-mecI 
genes strongly repress mecA expression, which is a survival disadvantage in the 
presence of a β-lactam antibiotic, it is likely that bla regulatory genes have played this 
role (72). In 1980 Stewart and Rosenblum observed that β-lactamase plasmid is a 
critical determinant for transduction of the methicillin resistance and reported that 
methicillin resistance tends to be unstable in clinical isolates when this plasmid is absent 
(137). These observations are understandable in view of the ability of the β-lactamase 
operon to stabilize mecA in some genetic backgrounds. The maintenance of a functional 
blaZ gene might be also useful for bacteria as a “first line defense” against first 
generation β-lactams (i.e. penicillins) or because it may be linked to other positively 
selected genes, as the cadmium resistance genes present in some β-lactamase plasmids. 
Moreover, β-lactamase likely causes little fitness cost as it is a secreted enzyme and 
much smaller than PBP2a, which is a transpeptidase with poor cross-link activity that 
has to be integrated into the cell-wall machinery. Therefore, one can speculate that there 
is a major advantage for MRSA strains to keep the β-lactamase locus (100), and in fact 
more than 95% of MRSA strains are still positive for bla genes (86), despite the fact 
that mecA can provide resistance to virtually all β-lactams. In short, β-lactamase 
regulatory genes seem to provide a compromise solution to the need for some control 
over PBP2a production to minimize the cost of maintaining mecA while also being able 
to express the protein in the presence of an antibiotic.  
A recent study by Oliveira and Lencastre has challenged the current model for 
the transcriptional control of mecA in clinical MRSA strains (107). The authors 
overexpressed in trans the wild-type mecI gene in a collection of prototype MRSA 
clinical strains. These strains came from different clonal types and some have wild-type 
mecA regulatory genes, while others have mutations in these genes. According to the 
current model, it was expected a significant decrease in the oxacillin resistance 
phenotype, particularly for those strains with SCCmec types I and IV-VII, which do not 
have mecI gene. However, for virtually all strains, there was no significant decrease in 
the resistance phenotype, suggesting the presence of other yet unidentified elements that 
might contribute to the control of the expression of β-lactam resistance. Interestingly, 
the only two strains showing a decrease in the resistance phenotype were negative for 
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the β-lactamase operon. This observation suggests that the other strains containing the 
β-lactamase operon are, in some way, protected by the negative effect of the 
overexpressed MecI repressor in terms of resistance expression. Previous studies 
showing that the bla regulatory genes can efficiently control the mecA gene along with 
the mec regulators favor this hypothesis (53, 99), although the disruption of MecI-
mediated repression directly by bla regulators has never been described. 
This thesis came in the wake of these studies that suggest new perspectives for 
the role of bla genes in the stabilization and regulation of mecA gene, and, 
consequently, on the phenotypic expression of methicillin resistance in clinical MRSA 
strains. 
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MATERIALS AND METHODS 
 
 
1. Bacterial strains and plasmids 
 
Culture media, reagents, buffer solutions and antibiotics are listed in ANNEX. 
The strains and plasmids used in this study are listed in Table 1. S. aureus cultures 
stored at -80ºC were routinely grown on TSB or TSA (Difco) with aeration at 37ºC. E. 
coli strains were grown on LB or LA (Roth) with aeration at 37 ºC. Culture media were 
supplemented with antibiotics, when appropriate, at the following concentrations: 
chloramphenicol at 10 µg/mL, ampicillin at 100 µg/mL, tetracycline at 10 µg/mL, 
CdCl2 at 50 µM, anidrotetracycline at 1 µg/mL and 2 µg/mL, and Isopropyl β-D-1-
thiogalactopyranoside (IPTG) ranging from 1 mM to 1000 mM.  
 
Table 1 - Strains and plasmids 
Strain/plasmid Relevant characteristics Reference 
Strains 
  
   S. aureus    
      COL Homogeneous MRSA SCCmec I;  
β-lactamase negative 
(109) 
      VNG17 Heterogeneous MRSA SCCmec IV; 
β-lactamase negative 
(108, 120) 
      RJP17 Heterogeneous MRSA SCCmec IV; 
β-lactamase negative 
(108, 120) 
      HT0350 Heterogeneous MRSA SCCmec V; 
β-lactamase negative 
(142) 
      MW2 Heterogeneous MRSA SCCmec IV; 
β-lactamase positive 
(6) 
      RN4220 MSSA strain, restriction-deficient 
mutagenized RN450 
 
(80) 
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Table 1 – Cont. 
Strain/plasmid Relevant characteristics Reference 
   
      COL-I COL + pGC2::mecI (107) 
      COL-I + pbla COL + pGC2::mecI + pbla This study 
      COL-I + blaIblaR1 COL + pGC2::mecI + 
pSPT181::Pspac::blaIblaR1 
This study 
      COL-I + OblaIblaR1 COL + pGC2::mecI + 
pSPT181::Pspac::OblaIblaR1 
This study 
      COL-I + blaR1 COL + pGC2::mecI + 
pSPT181::Pspac::blaR1 
This study 
 
      COL-I + OblaR1 COL + pGC2::mecI + 
pSPT181::Pspac::OblaR1 
This study 
 
      COL-I + blaI COL + pGC2::mecI + 
pSPT181::blaI 
This study 
      COL-I + NTDblaR1 
     
COL + pGC2::mecI + 
pSPT181::Pspac::NTDblaR1 
This study 
      COL-I + ∆NTDblaR1 COL + pGC2::mecI + 
pSPT181::Pspac::∆NTDblaR1 
This study 
      COL-I + L3blaR1 COL + pGC2::L3blaR1 
 
This study 
      VNG17-I VNG17 + pGC2::mecI 
 
(107) 
      VNG17 + pbla VNG17 + pbla 
 
This study 
      VNG17-I + pbla VNG17 + pGC2::mecI + pbla This study 
 
      RJP17-I RJP17 + pGC2::mecI 
 
(107) 
      RJP17 + pbla RJP17 + pbla 
 
This study 
      RJP17-I + pbla RJP17 + pGC2::mecI + pbla 
 
This study 
      HT0350-I 
 
HT0350 + pSPT181::mecI This study 
      HT0350 + pbla HT0350 + pbla 
 
This study 
      HT0350-I + pbla HT0350 + pSPT181::mecI + pbla 
 
This study 
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Table 1 – Cont. 
Strain/plasmid Relevant characteristics Reference 
   
      MW2-I MW2 + pGC2::mecI (107) 
   E. coli  
 
      NEB 10-beta Competent 
E. coli 
araD139 ∆(ara-leu)7697 fhuA 
lacX74galK (Ф80 ∆(lacZ)M15) mcrA 
galU recA1 endA1 nupG rpsL (Str
R
) 
∆(mrr-hsdRMS-mcrBC) 
New England 
BioLabs 
Plasmids 
 
 
 
      pbla Native β-lactamase plasmid from 
MW2 strain, Amp
r
,
 
Cd
r
 
(6) 
      pGC2 High-copy number E. coli-S. aureus 
shuttle plasmid, Cm
r
 
(104) 
      pSPT181 High-copy number E. coli-S. aureus 
shuttle plasmid, Tc
r
 
(69) 
      pKOR1 Thermosensitive E. coli-S. aureus 
shuttle plasmid, Cm
r
 
(7) 
      pSPT181::Pspac pSPT181 with Pspac promoter and 
repressor lacI cloned from pDH88 
(154) 
Arêde, P. 
      pGC2::mecI mecI gene from N315 strain cloned 
into pGC2 
(107) 
      pSPT181::Pspac:: 
      blaIblaR1 
blaR1blaI fragment from MW2 
cloned into pSPT181 under control 
of Pspac promoter 
Arêde, P. 
      pSPT181::Pspac:: 
      OblaIblaR1 
blaR1blaI fragment with operator 
region from MW2 cloned into 
pSPT181 under control of Pspac 
promoter 
Arêde, P. 
      pSPT181::Pspac::blaR1 
 
blaR1 gene from MW2 cloned into 
pSPT181 
Arêde, P. 
      pSPT181::Pspac::OblaR1 
 
blaR1 gene with operator region 
from MW2 cloned into pSPT181 
Arêde, P. 
      pSPT181::blaI blaI gene from MW2 cloned into 
pSPT181 
This study 
      pSPT181::Pspac:: 
      NTDblaR1 
 
N-terminal cytoplasmic sensor 
domain of blaR1 cloned into 
pSPT181 
 
This study 
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Table 1 – Cont. 
Strain/plasmid Relevant characteristics Reference 
   
      pSPT181::Pspac:: 
      ∆NTDblaR1 
Truncated N-terminal domain of blaR1 
gene (without loop 3 metalloprotease) 
cloned into pSPT181 
This study 
      pGC2::L3blaR1 504 bp of blaR1 N-terminal domain 
containing the loop 3 metalloprotease 
cloned into pGC2 
This study 
      pKOR1::blaR1  1.0 kb upstream and downstream 
blaR1 vicinities cloned into pKOR1 
This study 
 
 
 
2. Molecular methods 
 
2.1 DNA isolation  
 
Total DNA from S. aureus was isolated from bacterial cultures with the Wizard 
Genomic DNA purification Kit (Promega) according to the manufacturer’s 
recommendation and using lysostaphin (10 µg/mL) and RNAse (10 µg/mL) in the lysis 
step (5). Alternatively, genomic DNA of S. aureus was isolated by a boiling prep with a 
lysis step at 37ºC for 30-60 minutes with 10 µg/mL of lysostaphin. Plasmid DNA was 
isolated from bacterial cultures with the High Pure Plasmid Isolation Kit (Roche). For S. 
aureus plasmid DNA isolation the cultures were incubated at 37ºC for 30-60 minutes 
with 10 µg/mL of lysostaphin in cell suspension buffer for an efficient cell-wall lysis. 
 
 
 
 
MATERIALS AND METHODS 
_____________________________________________________________________________ 
24 
 
2.2 DNA purification and manipulation 
 
Restriction endonuclease digestions (New England Biolabs) were performed 
according to the manufacturer’s directions. Dephosphorylation of vector arms and insert 
ligation was performed with Rapid DNA Dephos & Ligation kit (Roche) according to 
the manufacturer’s recommendations. Routine PCR was performed with Go Taq Flexi 
DNA polymerase (Promega). PCR primers and reagents are listed in ANNEX. PCR 
amplification of cloning inserts was obtained with the proof reading Pfu Turbo DNA 
Polymerase (Agilent). Recombination between PCR products (containing attB sites) 
and a donor vector (containing attP sites) were performed with Gateway BP Clonase II 
enzyme (Invitrogen) according to the manufacturer’s directions. 
DNA purification from PCR and digestion reactions was performed with High 
Pure PCR Product Purification kit (Roche). For ligation protocols, the inserts and 
linearized plasmids were resolved in a low melting agarose gel (1%) (Invitrogen) and 
DNA bands were purified with Gene Clean Turbo kit (MP Biomedicals), following the 
manufacturer’s recommendations. 
Transformation of recombinant plasmids into NEB 10-beta Competent E. coli 
cells (New England Biolabs) was performed in accordance with the manufacturer’s 
recommendations. Selection of transformants was performed with ampicillin at 100 
µg/mL. 
 
 
2.3 Electrophoresis analysis of PCR and DNA restriction reactions 
 
Routine electrophoresis analysis of PCR products and restriction reactions was 
analyzed by agarose gel electrophoresis at 0,8% (p/v) (Invitrogen) with Tris-Acetate-
EDTA (TAE) at 85 V. 25 µL of a 1:10 dilution of Gel Red (Biotium) was added to each 
100 mL of agarose. For band visualization, gel images were acquired in a 
transilluminator (Gel Doc, Quantity One 4.5.0, BioRad). Molecular weight estimations 
of the DNA fragments were made against 1 kb (kilobase) Plus DNA Ladder 
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(Invitrogen). DNA was quantified by U.V. spectroscopy with NanoDrop ND-1000 
instrument (Thermo Scientific). 
 
 
2.4 Electroporation of recombinant plasmids into S. aureus 
 
Recombinant plasmids were introduced into electrocompetent restriction minus 
S. aureus strain RN4220 as previously described (122). Briefly, DNA and competent-
cells were mixed in an electroporation cuvette with 0.2 cm electrode and submitted to 
electroporation in a Gene Pulser (BioRad) at the following settings: resistance 200 Ω, 
capacitance 25 µF, and voltage 2,5 kV.  Immediately after the electric shock 1 mL of 
TSB was added to the cuvette. The mixture was transferred to an eppendorff tube and 
placed in a rotating device at 37ºC for one hour. Aliquots of 200 and 20 µL were spread 
onto TSA supplemented with antibiotic and incubated overnight at 37ºC.  
 
 
2.5 Preparation of transducing lysates and transduction 
 
Recombinant plasmids were transferred from strain RN4220 to other S. aureus 
strains by bacteriophage-mediated transduction as previously described (110). Briefly, 
for preparation of transducing lysates, donor strains were grown on BHI slants (Difco) 
overnight at 37ºC. Cells were collected with 1 mL of TSB and calcium chloride was 
added to a final concentration of 5mM. Phage 80α lysate was serial 10-fold diluted (10-2 
to 10
-7
) in phage buffer. 10 µL of cell suspension was mixed with 10 µL of each phage 
dilution and 3 mL of phage top agar, equilibrated at 45ºC and supplemented with 5mM 
of CaCl2. The mixture was poured into plates containing phage bottom agar and 
incubated overnight at 30ºC. On the following day 2 mL of phage buffer were added to 
plates showing confluent lysis. Plates were kept at 4ºC for one hour. The phage top agar 
and the phage buffer were collected into a 15 mL falcon tube and vigorously vortexed in 
order to disrupt the agar. The tubes were kept for one more hour at 4ºC. The suspension 
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was centrifuged at 4500 rpm for 20 minutes at 4ºC. The supernatant was collected and 
filtered through a 0,45 µL sterile filter. 
For transduction, recipient strains were grown overnight in a BHI slant. 100 µL 
of cell suspension supplemented with 5mM of CaCl2 were added to 10 µL and 100 µL 
of the phage lysate from donor strain and phage buffer was added to a final volume of 
300 µL. The mixture was incubated for 20 minutes at 37ºC and 3 mL of 0,3GL top agar, 
equilibrated at 45ºC, were added. The mixture was then poured onto plates of 0,3GL 
agar with a gradient of selective antibiotic. Plates were incubated overnight at 37ºC. 
 
 
 
3. Overexpression of β-lactamase regulatory genes 
 
A DNA fragment containing the wild-type blaI coding region and the putative 
ribosomal binding site from the prototype strain MW2 was amplified by PCR with the 
high-fidelity Pfu Turbo DNA polymerase (Agilent) with primers blaF5 and blaR9 
(ANNEX) containing the recognition sequences for endonucleases PstI and BamHI, 
respectively. After double digestion and purification, the inserts were directionally 
cloned into the multiple cloning site of pSPT181. pSPT181 is a high-copy number E. 
coli/ S. aureus shuttle plasmid with resistance determinants to ampicillin (E. coli) and 
tetracycline (S. aureus), with a T6 promoter upstream to the multiple cloning site. The 
integrity of the insert was verified by DNA restriction and PCR analysis. Two 
recombinant plasmids were then introduced in parallel into the restriction-deficient S. 
aureus strain RN4220 by electroporation and then transduced into the COL + 
pGC2::mecI strain using phage 80α. Using the same strategy, a PCR fragment 
containing the metalloprotease loop 3 (L3) domain, obtained from strain MW2, was 
amplified with the Pfu Turbo DNA polymerase with primers blaL3F1/ EcoR1 and 
blaL3R1/ BamHI (ANNEX), cloned into pGC2 plasmid and introduced into strain COL 
+ pSPT181::mecI in two experimental replicas. pGC2 is a high-copy number E. coli/ S. 
aureus shuttle plasmid with resistance determinants to ampicillin (E. coli) and 
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chloramphenicol (S. aureus), in which the multiple cloning site is flanked by the strong 
SP6 and T7 bacteriophage promoters. 
The N-terminal cytoplasmic domain of blaR1 with or without the 
metalloprotease L3 domain were also PCR amplified with the Pfu polymerase along 
with the putative ribosomal binding site, from the prototype strain MW2, with primers 
blaR1F2, blaR1F3 and blaR10 (ANNEX) containing recognition sequences for 
endonuclease XmaI. After digestion of PCR fragments, linearization of expression 
vector pSPT181::Pspac and dephosphorylation of vector arms, fragments were ligated 
to the multiple cloning site of the vector. The recombinant plasmids were then 
transformed and propagated in NEB 10-beta Competent E. coli cells. After the 
verification of insert integrity and orientation, the recombinant plasmids were 
electroporated into RN4220 and subsequently transduced to COL + pGC2::mecI in two 
experimental replicas. 
 
 
 
4. Genetic knock-out of β-lactamase regulatory genes 
     (Work in progress) 
 
Genetic knock out’s were done by allelic replacement with inducible counter-
selection using pKOR1 plasmid (7). This plasmid is an E. coli/ S. aureus shuttle vector 
with specific characteristics. It contains a lambda recombination cassette allowing 
efficient cloning without the use of restriction enzymes and ligases. This cassette 
encodes for ccdB, an E. coli gyrase inhibitor that suppresses the growth of cells 
containing pKOR1 without insert. pKOR1 has a thermosensitive origin of replication in 
S. aureus which facilitates the chromosomal integration at non-permissive temperature 
(43ºC). Moreover, in S. aureus the plasmid allows selection for chromosomal excision 
and plasmid segregation via inducible antisense expression of the essential gene secY 
that is controlled by an anydrotetracycline (ATc) inducible promoter (Fig. 5). 
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For the genetic knock out of blaR1, DNA fragments of 1 kb were PCR amplified 
upstream and downstream of the regulator, using the primers attB1-blaF6 and blaR6-
BamHI, for the upstream fragment, and BamHI-blaF8 and attB2-blaR7, for the 
downstream fragment (ANNEX). The PCR products were digested with BamHI and 
ligated with T4 ligase. The ligation product was used for recombination with pKOR1 
and the recombinant products were transferred to NEB 10-beta Competent E. coli cells. 
The resulting plasmid, pKOR1::blaR1 was transferred via electroporation to the S. 
aureus restriction minus strain RN4220 and then transduced into the parental strain, 
using phage 80α and selection with 10 µg/ mL of chloramphenicol. 
Attempts to insert pKOR1::blaR1 in strains with bla locus integrated into the 
chromosome failed due to the resistance of those strains to bacteriophage infection. 
Therefore we set up a strategy to generate genetic knock-out’s in the -lactamase 
plasmid which is not single-copy. For the integration of recombinant pKOR1::blaR1 
Figure 5 - Map of pKOR1. repF (Replication gene of pE194ts), secY570 (N-terminal 570 nucleotides 
of secY including ribosome binding site), cat (chloramphenicol acetyltransferase), attP (phage lambda 
attachment site), ori(-) (ColE1 plasmid replication origin), bla (β-lactamase). (+) or (-) indicates gram-
positive (+) and gram-negative (-) bacteria (7).    
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into β-lactamase plasmid, COL strain transformed with both plasmids was grown at 
43ºC on TSB supplemented with 10 µg/mL of chloramphenicol. A transducing-lysate of 
this culture was prepared and transduced back to strain COL with chloramphenicol and 
ampicillin selection, in order to select pbla-pKOR1::blaR1 co-integrates only. Next, 
one colony was picked and inoculated in TSB supplemented with 10 µg/mL of 
chloramphenicol at 30ºC, a permissive temperature, which enables co-integrate 
resolution. A transducing-lysate of this culture was prepared and transduced back to 
strain COL with ampicillin selection and anydrotetracyclin counter selection at 1 and 2 
µg/mL. Control experiments were made without anydrotetracyclin. Plates were   
incubated at 30ºC for 2 days. Deletion of blaR1 was confirmed by PCR amplification 
with primers blaF9 and blaR8 (ANNEX). 
 
 
 
5. Phenotypic analysis 
 
Susceptibility to oxacillin was routinely analyzed by disc diffusion method with 
1 µg oxacillin discs prepared in-house. The cultures were homogeneously spread in a 
TSA plate with a swab and the antibiotic discs were carefully placed. The plate was 
incubated at 30ºC for 48 hours. The growth inhibition area was measured with a scale 
and compared with parental strains.  
To infer the contribution of blaZ gene, TSA plates were supplemented with 2 
µg/mL of clavulanic acid, a β-lactamase inhibitor, and susceptibility to oxacillin and 
penicillin was evaluated with 1 µg and 10 U diffusion discs, respectively. IPTG was 
added into TSA plates in a concentration range of 1 - 1000 mM when appropriate. 
The parental and recombinant strains were tested by population analysis profiles 
(PAPs), as previously described (70). In short, 10 mL drops of 10
0
, 10
-1
, 10
-2
, 10
-3
, 10
-4
, 
10
-5
, 10
-6
 and 10
-7
 dilutions of the overnight cultures were plated on TSA plates 
containing 0, 0.75, 1.5, 3, 6, 12.5, 25, 50, 100, 200, 400 and 800 mg/mL of oxacillin. 
The plates were tipped onto a 90° angle, and the drops migrated in parallel ways across 
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the plate to the opposite side. The plates were then incubated at 30°C. For each oxacillin 
concentration, colonies were counted for the first dilution with non-confluent growth 
after 24 h and 48 h of incubation at 30ºC. 
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RESULTS 
 
 
According to recent data from our laboratory, the oxacillin resistance phenotype 
of most MRSA strains is not affected by the overexpression in trans of the mecA 
repressor (107). This surprising observation contradicts the current model and suggests 
the presence of other elements involved in the transcriptional control of mecA gene. The 
only two strains for which a decrease of the oxacillin-resistance phenotype was 
observed were negative for the -lactamase locus, suggesting that this locus might be 
involved in that phenomenon. In order to explore the putative effect of the β-lactamase 
operon in the protection against the repressive effect of mecI, several exploratory 
experiments were performed, as described below. 
 
 
1. Introduction of native β-lactamase plasmid into prototype strains 
 
1.1 Introduction of native β-lactamase plasmid into strain COL-I  
 
The prototype strain COL has a high and homogeneous level of oxacillin 
resistance, is negative for mecI and has a partially deleted mecR1, is naturally negative 
for the β-lactamase locus and has been used in many studies addressing the oxacillin-
resistance mechanisms. Recombinant strain COL-I, overexpressing in trans the mecA 
repressor, pGC2::mecI, is characterized by a massive decrease in the resistance level. In 
order to evaluate the role of β-lactamase operon in the observed “MecI-protection 
effect”, we have first introduced the native β-lactamase plasmid into strain COL-I. 
Strain MW2, similarly to COL, has no mecI and a partially deleted mecR1, but is β-
lactamase positive and its oxacillin resistance phenotype was not affected by the mecI 
overexpression. Moreover, MW2 genome and plasmid sequence have been determined 
(6). The native β-lactamase plasmid from MW2 strain (pbla) was introduced into COL-I 
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strain via 80α bacteriophage-mediated horizontal gene transfer with selection for 
ampicillin resistance. The strategy turned out successful with the introduction of the 
large β-lactamase plasmid into strain COL first, followed by the introduction of the 
recombinant pGC2::mecI.  The presence of both plasmids was confirmed by restriction 
analysis and PCR detection of the β-lactamase operon and mecI gene. This experiment 
was done in two independent replicas. 
When oxacillin susceptibility was tested, it was observed that the transformant 
COL-I in the presence of β-lactamase plasmid restored the resistance phenotype of 
strain COL in spite of the overexpression of mecI gene. These observations were also 
confirmed by population analysis profile (PAP) assays (Fig. 6 and Table 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Relevant genotype 
Oxacillin-disc inhibition 
halo (mm) 
   
COL mecI 
-
 ∆mecR1 bla - 8 
COL-I mecI ∆mecR1 bla - 32 
COL-I + pbla mecI ∆mecR1 blaZ blaI blaR1 7 
Table 2 - Oxacillin-resistance of parental strain COL and recombinant strains 
 
 
 
1
 
 
 1 2 
3 4 
2 
 
3 
 
Figure 6. Phenotypic expression of oxacillin resistance in COL and recombinant strains.  
A. Disc diffusion test 1: COL; 2: COL-I; 3: COL-I + pbla; B. Population analysis profile. 
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 1 2 
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A B 
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1.2  Introduction of native β-lactamase plasmid into VNG17 and 
VNG17-I strains 
 
Strain VNG17 and VNG17-I (overexpressing mecI) were transformed with the 
β-lactamase plasmid of strain MW2 (pbla). Given that strain COL-I showed a revertable 
phenotype in the presence of the β-lactamase plasmid we aimed to confirm these 
observations in other strains also negative for the β-lactamase locus. Strain VNG17 was 
the only other strain in which the overexpression of mecI caused a decrease in the 
oxacillin-resistance. Similarly to COL, strain VNG17 has no mecI and partially deleted 
mecR1 but has a low-level resistance to oxacillin. The procedure was the same for 
introduction of the native β-lactamase plasmid into COL-I strain. The plasmid from 
prototype MW2 strain was introduced into VNG17 and VNG17-I strains via 80α 
bacteriophage-mediated horizontal gene transfer. For strain VNG17-I the protocol was 
also more successful with introduction of the β-lactamase plasmid into strain VNG17 
first, following introduction of the pGC2::mecI. The presence of the plasmids was 
confirmed by restriction analysis and PCR detection of the β-lactamase operon and mecI 
gene.  
As shown in Fig. 7 and Table 3, the introduction of the β-lactamase plasmid 
either in the parental or recombinant strain with mecI overexpression, caused a massive 
decrease in the susceptibility to oxacillin. In addition, the parental strain transformed 
with pbla showed a remarkable shift from low-level and heterogeneous to high-level 
and homogeneous expression of oxacillin resistance. 
 
 
 
 
 
 
 
 
1 
2 
3 
4 
2 
4 
RESULTS 
_____________________________________________________________________________ 
34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Relevant genotype 
Oxacillin-disc inhibition 
halo (mm) 
   
VNG17 mecI 
-
 ∆mecR1 bla - 33/53a 
VNG17 + pbla mecI 
-
 ∆mecR1 blaZ blaI blaR1 13 
VNG17-I mecI ∆mecR1 bla - 57 
VNG17-I + pbla mecI ∆mecR1 blaZ blaI blaR1 33/38a 
a 
Heterogeneous population 
Table 3 - Oxacillin-resistance of parental strain VNG17 and recombinant strains 
A B Oxacillin (µg/mL) 
1 2 
3 4 
Figure 7 - Phenotypic expression of oxacillin resistance in VNG17 and recombinant strains.  
A. Disc diffusion test 1: VNG17; 2: VNG17 + pbla; 3: VNG17-I; 4: VNG17-I + pbla; B. Population 
analysis profile. 
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1.3  Introduction of native β-lactamase plasmid into RJP17 and RJP17-I 
strains 
 
RJP17 strain is also a -lactamase negative strain, which belongs to the same 
clone of VNG17 and was isolated in the same country and time period. Similarly to 
VNG17, RJP17 is mecI negative, has a partial deleted mecR1 and expresses low level 
resistance to oxacillin. However, it was not detected any alteration in the oxacillin 
resistance phenotype upon the overexpression of mecI (strain RJP17-I) (107). 
Nevertheless, we have also evaluated the effect of the β-lactamase locus in this strain. 
Introduction of the β-lactamase plasmid in the recombinant strain overexpressing the 
mecI gene, RJP17-I, was also tested. The procedure was exactly the same as performed 
for VNG17 and VNG17-I strains. Results are summarized in Fig. 8 and Table 4.  
Since the resistant phenotype was not affected by the overexpression of MecI, 
the presence of pbla in strain RJP17-I did not cause any significant alterations. 
However, similarly to what was observed for strain VNG17, the parental strain 
transformed with pbla shifted to a high-level and homogeneous expression profile of 
oxacillin resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 - Phenotypic expression of oxacillin resistance in RJP17 and recombinant strains.  
A. Disc diffusion test 1: RJP17; 2: RJP17 + pbla; 3: RJP17-I; 4: RJP17-I + pbla; B. Population analysis 
profile. 
A B 
Oxacillin (µg/mL) 
1 2 
3 4 
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1.4  Introduction of native β-lactamase plasmid into HT0350 strain 
 
HT0350 strain is other -lactamase negative strain but with a more extensive 
deletion of mecR1 due to the presence of IS431, a typical characteristic from SCCmec 
type V strains. While strains COL, VNG17, RJP17 still have a complete N-terminal 
domain of mecR1 with the four-transmembrane segments (960 amino acids), strain 
HT0350 has only the first 36 amino acids of the MecR1. Similarly to VNG17 and 
RJP17, HT0350 is negative for mecI gene and expresses low-level resistance to 
oxacillin. The plasmid from prototype MW2 strain was introduced into this strain, via 
80α bacteriophage-mediated horizontal gene transfer, in order to test, the effect of the β-
lactamase locus. As we can see in Fig. 9 and Table 5 the β-lactamase plasmid promoted 
a significant increase in the oxacillin resistance phenotype. 
Since strain HT0350 is intrinsically resistant to chloramphenicol, it was not 
included in previous mecI overexpression studies with plasmid pGC2, which carries a 
chloramphenicol resistance marker. Therefore, mecI was cloned in pSPT181, which 
carries a tetracycline resistance marker, and HT0350 phenotypic expression of 
oxacillin-resistance was evaluated in the presence of mecI overexpression in trans. 
Strain Relevant genotype 
Oxacillin-disc inhibition 
halo (mm) 
   
RJP17 mecI 
-
 ∆mecR1 bla - 27/42a 
RJP17 + pbla mecI 
-
 ∆mecR1 blaZ blaI blaR1 15 
RJP17-I mecI ∆mecR1 bla - 27/44a 
RJP17-I + pbla mecI ∆mecR1 blaZ blaI blaR1 38/40a 
a 
Heterogeneous population 
Table 4 - Oxacillin-resistance of parental strain RJP17 and recombinant strains 
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Thereafter, the β-lactamase plasmid was introduced in the HT0350-I strain, similarly to 
the above experiments. The results of the mecI overexpression and the later introduction 
of pbla are shown in Fig. 9 and Table 5. The presence of the β-lactamase plasmid in the 
parental strain promoted a shift from low-level and heterogeneous to high-level and 
homogeneous phenotypic expression of oxacillin resistance, and the recombinant strain 
HT0350-I restored the phenotype of the parental strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Relevant genotype 
Oxacillin-disc inhibition 
halo (mm) 
   
HT0350 mecI 
-
 ∆mecR1 bla - 35 
HT0350 + pbla mecI 
-
 ∆mecR1 blaZ blaI blaR1 16 
HT0350-I mecI ∆mecR1 bla - 56 
HT0350-I + pbla mecI ∆mecR1 blaZ blaI blaR1 40 
Table 5 - Oxacillin-resistance of parental strain HT0350 and recombinant strains 
Figure 9 - Oxacillin susceptibility test of parental strain HT0350 and recombinant strains. 
 A. Disc diffusion test. 1: HT0350; 2: HT0350 + pbla; 3: HT0350-I; 4: HT0350-I + pbla; B. Population 
analysis profile. 
Oxacillin (µg/mL) 
A B 
1 2 
3 4 
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Once we have confirmed the role of β-lactamase plasmid in the phenotypic 
expression of oxacillin-resistance and the interference with the mecI-mediated 
expression of mecA, we aimed to further experiments to investigate which element(s) of 
the β-lactamase operon would be, specifically, involved. 
 
 
2. Phenotypic effect of clavulanic acid  
 
Clavulanic acid is an inhibitor of the β-lactamase (114) and, as such, its 
incorporation in the oxacillin susceptibility testing allows to infer the specific 
contribution of blaZ gene in the phenotypic expression of oxacillin resistance. For this 
purpose, the oxacillin-resistance phenotype was re-evaluated for all parental and 
recombinant strains in TSA plates supplemented with 2 µg/mL of clavulanic acid. Table 
6 shows the phenotypic effect of clavulanic acid in all parental and recombinant strains. 
As a control, we tested the susceptibility to penicillin (coded by blaZ) in the presence 
and absence of clavulanic acid. The addition of clavulanic acid caused an increase in the 
susceptibility to penicillin in all strains positive for pbla. Regarding the oxacillin-
resistance phenotype, all strains presented a similar resistance phenotype in the presence 
and absence of clavulanic acid. 
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a 
Heterogeneous population 
Inhibition halo diameter (mm) 
 
Oxa disc Pen disc 
Clavulanic acid 
(µg/mL) 
0 2 0 2 
MW2 30/39
a 
29/39
a 
8 11 
MW2-I 30/40
a 
30/40
a 
7 11 
COL 11 12 7 7 
COL-I 15/40
a 
19/39
a 
28 27 
COL-I + pbla 13 13 7 7 
VNG17 34/52
a 
31/51
a 
15/45
a 
15/46
a 
VNG17 + pbla 17/20
a 
12/17
a 
7 10 
VNG17-I 58 57 50 50 
VNG17-I + pbla 35 35 7 10 
RJP17 29/39
a 
27/38
a 
15/35
a 
14/34
a 
RJP17 + pbla 16 16 7 7 
RJP17-I 29 28 16 15 
RJP17-I + pbla 34 35 7 11 
HT0350 35 35 7 11 
HT0350 + pbla 16 16 7 22 
HT0350-I 50 50 43 43 
HT0350-I + pbla 38 37 7 7 
Table 6 - Clavulanic acid effect on oxacillin and penicillin-resistance phenotype 
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3. Introduction of β-lactamase regulators into COL-I strain 
 
In order to explore the mechanisms by which the bla regulators interfere with 
MecI repression and “boost” the phenotypic expression of oxacillin resistance, 
recombinant plasmids containing only the regulators were introduced into COL-I strain 
via bacteriophage-mediated horizontal gene transfer.  
 
 
3.1  Introduction of blaIblaR1 into COL-I strain 
 
Previously, the blaIblaR1 coding region has been cloned in pSPT181 plasmid 
under the control of the inducible promoter Pspac (Arêde, P., unpublished data). At the 
same time, a similar construct was performed cloning this segment with the operator 
region, OblaIblaR1. These constructs were introduced into COL-I strain and oxacillin 
susceptibility was tested in the presence of several concentrations of IPTG. As shown in 
Table 7, the resistance phenotype of parental strain COL could not be restored in strain 
COL-I transformed with the β-lactamase regulators. Furthermore, the expression of 
these genes caused an increase in the susceptibility. The phenotype was not influenced 
by the presence or absence of the operator region, since it was not observed any 
significant difference between the two sets of experiments. 
 
 
3.2  Introduction of blaR1 and blaI genes into COL-I strain 
 
Since introduction of both regulators simultaneously did not reproduce the effect 
of the whole β-lactamase plasmid, showing an even more susceptible phenotype, the 
two regulators were tested separately.  
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The blaR1 gene has been previously cloned into pSPT181 plasmid under the 
control of the inducible promoter, Pspac, as well as the same sequence plus the operator 
region, OblaR1 (Arêde, P., unpublished data). The blaI gene was cloned in the pSPT181 
plasmid under the control of the constitutive promoter T6. The constructs were 
introduced into strain COL-I and the susceptibility to oxacillin was tested. The presence 
of either β-lactamase regulator did not restore the oxacillin-resistance phenotype, as 
previously seen in the presence of pbla. Indeed, introduction of blaR1 gene originates a 
phenotype even more susceptible than COL-I strain, similar to the phenotype upon 
introduction of blaR1blaI. The presence of the operator region did not seem to influence 
the resistance phenotype, since the halo diameters were similar. The presence of only 
blaI gene had no effect in the resistance phenotype of strain COL-I, presenting a similar 
halo diameter (Table 7). 
 
 
3.3  Introduction of blaR1 domains into COL-I strain 
 
In order to overcome what seem to be a toxic effect from BlaR1, two short 
BlaR1 domains were cloned into the expression vector pSPT181, under the control of 
the inducible promoter Pspac. The first constructed, called NTDblaR1, contains the 
initial 817 bp of blaR1 and includes the zinc metalloproteases domain, thought to be 
involved in the signal transducing. The second construct, called ∆NTDblaR1, contains 
the initial 511 bp of blaR1 and do not include the zinc metalloprotease domain. The 
constructs were introduced into COL-I strain and susceptibility to oxacillin was tested 
under the presence of different IPTG concentrations. The results are shown in Table 7. 
Neither construct showed an influence in the increased resistant phenotype seen above 
with introduction of the whole plasmid. Moreover, the overexpression of these BlaR1 
domains causes an increase in the susceptibility. 
Since even the smaller blaR1 constructs seemed to increase, as well, the 
oxacillin susceptibility of COL-I strain, we designed a construct containing the coding 
region for L3 metalloprotease domain only, which was cloned into pGC2 plasmid and 
introduced into COL + pSPT181::mecI. This construct is the smallest possible in order 
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to include the metalloprotease domain, with 504 bp only, corresponding to the 
cytoplasmic loop 3. However, the presence of this element, did not restore the resistance 
phenotype of COL strain, originating a similar oxacillin-resistance phenotype to strain 
COL-I. 
 
 
 
Strain Relevant genotype IPTG (mM) 
Oxacillin-disc 
inhibition halo 
(mm) 
COL mecI
-
 ∆mecR1 bla- - 8 
COL-I mecI ∆mecR1 bla- - 33 
COL-I 
+pSPT181::Pspac:: 
blaR1blaI 
mecI ∆mecR1 
blaR1 blaI 
0 32/45
a 
100 40 
COL-I 
+pSPT181::Pspac:: 
OblaR1blaI 
mecI ∆mecR1 
blaR1 blaI 
0 39 
100 40 
COL-I 
+pSPT181::Pspac:: 
blaR1 
mecI ∆mecR1 
blaR1 blaI- 
0 37/15
a 
100 41/19
a 
COL-I 
+pST1P81::Pspac:: 
OblaR1 
mecI ∆mecR1 
blaR1 blaI- 
0 40 
100 39 
COL-I 
+pSPT181::Pspac:: 
NTDblaR1 
mecI ∆mecR1 
∆blaR1 blaI- 
0 46/24
a 
100 40/23
a 
COL-I 
+pSPT181::Pspac:: 
∆NTDblaR1 
mecI ∆mecR1 
∆blaR1blaI- 
0 41/20
a 
100 44/21
a 
COL-I + 
pGC2::blaR1L3 
mecI ∆mecR1 
∆blaR1blaI- 
- 32 
COL-I + 
pSPT181::blaI  
mecI ∆mecR1 
blaR1
-
 blaI 
- 37
 
a 
Heterogeneous population 
Table 7 - Oxacillin-resistance of strain COL transformed with β-lactamase regulators 
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4. Deletion of bla regulators from native β-lactamase plasmid 
 
The previous attempts to introduce the bla regulators into COL-I strain turned 
out to be unsuccessful, since the introduction of blaR1 gene and its domains caused an 
increase in the oxacillin susceptibility, suggesting a toxic effect. We set-up a knock out 
experiment by allelic replacement, with inducible counter-selection (7), to delete the β-
lactamase regulators. Attempts to perform this experiment in strains with bla genes 
integrated into the chromosome (i.e. in single copy) were not successful because these 
strains were not amenable to genetic manipulations (S. aureus is not transformable and 
these strains were resistant to bacteriophage infection). Therefore, we decided to 
construct the genetic knock-outs in pbla plasmid which is not single-copy and, as such, 
our strategy became more complex with many purifying steps by bacteriophage 
transduction. These experiments are still in progress by the time this thesis is being 
prepared. 
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DISCUSSION AND CONCLUSION 
 
 
Induction of β-lactam resistance in S. aureus is triggered by the binding of β-
lactam molecules to the extracellular domain of the sensor-transducer protein. This 
binding promotes a conformational change, which is propagated intramolecularly and 
leads to the activation of the cytoplasmic inducer domain by auto-proteolysis. Soon 
after these events, there is a direct or indirect inactivation of the promoter-bound 
repressor, which allows the expression of the resistance genes (155). Despite the fact 
that the β-lactamase genes confer resistance to penicillins only, its regulatory genes can 
efficiently induce the expression of mecA gene, which codes for broad-spectrum β-
lactam resistance. This happens because the β-lactamase repressor, BlaI, has high 
similarity to the mecA repressor, MecI, and can bind to the operator region and repress 
mecA transcription (46). This cross-talk is not valid for the sensor-transducers, which 
are not interchangeable and are only active against the cognate repressors (99). 
In the so-called “pre-MRSA” strains (138), the presence of mecI-mecR1 system,  
results in a tight repression of PBP2a synthesis and full induction of methicillin 
resistance takes up to 48 hours. In these strains the production of PBP2a is not altered 
whether or not the strains also contain the blaI-blaR1 system (83). Probably, this 
happens because MecI is a very strong repressor of mecA expression (10). As a 
consequence of these observations, it has been assumed that high-level resistance, as 
seen in many contemporary MRSA strains, requires a non-functional mecI-mecR1 
regulatory locus (62, 81). 
Based on previous studies that claimed the influence of unknown elements in the 
control and regulation of mecA gene, the ability of bla genes to control mecA expression 
efficiently, and recent data from our laboratory, suggesting that the bla locus might be 
responsible for the stability of the oxacillin-resistance phenotype upon overexpression 
of mecI, the purpose of this work was to clarify the role of the β-lactamase operon in the 
phenotypic expression of -lactam resistance in clinical MRSA strains. 
First, we designed a strategy to demonstrate the role of the β-lactamase locus in 
the expression of oxacillin resistance and its ability to interfere with mecI-mediated 
repression of mecA.  In order to do so, a native β-lactamase plasmid was purified from 
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the prototype strain MW2 and introduced into the prototype β-lactamase negative strain 
COL. MW2 was isolated in USA in 1998. It belongs to the MLST sequence type 1, 
carries the SCCmec type IV and has non-functional mecI-mecR1 system. It expresses a 
heterogeneous level of resistance to oxacillin. MW2 genome and native plasmid 
sequences are available (6), which facilitates the genetic manipulations. Strain COL was 
isolated in UK in 1961. It belongs to the sequence type 250, carries the SCCmec type I, 
has non-functional mecI-mecR1 system and is highly and homogenous resistant to 
oxacillin (109). It has a constitutive expression of mecA and is naturally negative for β-
lactamase. Strain COL is a reference strain used in many studies addressing the 
mechanisms of β-lactam resistance (28) and its genomic sequence is also available 
(109). Moreover, upon overexpression of mecI in this strain (COL-I strain), a dramatic 
decrease in the oxacillin-resistance phenotype was observed (107). Therefore, the 
COL/COL-I pair of parental/recombinant strains is an excellent “reporter” system to 
probe the effect of genetic determinants in the phenotypic expression of oxacillin-
resistance. 
 The introduction of the intact native β-lactamase plasmid (pbla) from strain 
MW2 into COL-I caused a remarkable reversion in the resistant phenotype, which was 
virtually the same of parental strain COL. Moreover, in strain COL-I + pbla the 
population analysis profile of oxacillin-resistance expression was identical to the 
parental strain. These observations demonstrate that the presence of the β-lactamase 
plasmid influences, in fact, the expression of oxacillin-resistance, by interfering with the 
MecI function, and point to a revision of the current model for the transcriptional 
control of mecA, defending that high level of resistance implies non-functional mecI 
gene. Here, we demonstrate that a recombinant strain overexpressing the repressor mecI 
could fully restore the high and homogenous level of resistance in the presence of the β-
lactamase plasmid. 
To further explore these observations, the native plasmid from prototype strain 
MW2 was also introduced into three other β-lactamase negative strains. Two of them, 
VNG17 and RJP17, were isolated in the same country and time period. They belong to 
the MLST sequence type 5, carry SCCmec type IV, and have non-functional mecI-
mecR1 system (108, 120). Interestingly, despite the fact that both strains are β-lactamase 
negative and have a heterogeneous expression profile of resistance, only strain VNG17 
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phenotype was affected by the mecI-overexpression experiments (106), which 
challenges our hypothesis about the influence of the β-lactamase plasmid. The β-
lactamase plasmid was introduced in the recombinant strains overexpressing the mecI 
gene (VNG17-I and RJP17-I), and also in the parental strains, since they present, unlike 
strain COL, a low-level resistance that allows the detection of positive effects on the 
phenotypic expression of resistance. Upon introduction of the β-lactamase plasmid, the 
effect of mecI overexpression in strain VNG17 was disrupted and the resistance level of 
the parental strain was restored, demonstrating, once again, the interference of β-
lactamase with the MecI-mediated repression of oxacillin resistance. Moreover, both 
parental strains transformed with the bla plasmid shifted from a low-level and 
heterogeneous to a high-level and homogenous resistance phenotype. These 
observations suggest that -lactamase genes not only interfere with the MecI-mediated 
repression but are also “boosters” of the phenotypic expression of oxacillin-resistance in 
MRSA strains. Strains COL, VNG17 and RJP17 have no mecI and a partial-deleted 
mecR1 but still with the full N-terminal inducer domain. In order to evaluate the effect 
of the truncated mecR1 on the previous observations, we have tested the effect of pbla 
into a fourth β-lactamase negative strain – strain HT0350. This strain belongs to MLST 
sequence type 377 and carries SCCmec type V, which is characterized by a non 
functional mecI and a virtually full deletion of mecR1 gene (67, 142). In fact, strain 
HT0350 has only the first 111 bp of the coding sequence of mecR1, which corresponds 
to a few 36 amino acids of the N-terminal domain attached to the membrane. By testing 
the effect of the β-lactamase plasmid in this strain, we expected to clarify the role of 
mecR1 gene on those puzzling observations concerning the effect of pbla on oxacillin 
resistance. Similarity to the previous strains, upon introduction of the β-lactamase 
plasmid, HT0350 turned from a low-level and heterogeneous to a high-level and 
homogeneous oxacillin-resistant strain. Furthermore, the mecI repressor was 
overexpressed in trans in HT0350 (strain HT0350-I) and the β-lactamase plasmid was 
introduced in that recombinant strain. The overexpression of mecI gene in strain 
HT0350 caused a massive decrease in the oxacillin-resistance phenotype, which was 
fully reverted upon introduction of pbla. Altogether, this set of experiments with the 
native bla plasmid from strain MW2 provides new important insights into the regulatory 
mechanism of mecA expression: the β-lactamase locus enhances the phenotypic 
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expression of oxacillin resistance in heterogeneous MRSA strains and disrupts the 
strong effect of MecI, which are two new unexpected functions for the bla locus.   
Prompted by these observations, we designed a series of experiments to clarify 
which determinant(s) of the β-lactamase plasmid were involved. We reasoned that the 
bla operon, more specifically, the bla regulators, would be the most plausible 
candidates. However, formally it cannot be excluded the possible influence of other 
elements present in the β-lactamase plasmid. 
Given that blaZ gene has no regulatory functions described so far, it was 
expected that, when alone, it would not influence the expression of oxacillin-resistance 
mediated by mecA gene. In order to exclude the putative effect of blaZ gene, we re-
evaluated the oxacillin-resistance in the presence of clavulanic acid, which is a specific 
β-lactamase inhibitor (114). Addition of clavulanic acid had no significant effect in the 
oxacillin-resistance phenotypes of MRSA strains transformed with pbla, with or without 
mecI-overexpression in trans. Therefore, the structural gene of the bla operon, blaZ, 
coding for penicillin-resistance is not involved in the enhancer effect of pbla on the 
phenotypic expression of oxacillin-resistance. 
We came up with a few working hypotheses for the mechanism of action of bla 
regulators on the expression of oxacillin resistance. First, we may assume that BlaI form 
heterodimers with MecI, with each monomer binding to a different dyad in the mecA 
operator region. In fact, the formation of functional BlaI-MecI heterodimers has already 
been described by McKinney et al (99). As BlaI-BlaR1 system is much more efficient 
than MecI-MecR1, which strongly represses mecA, we may speculate that promoter-
bound MecI-BlaI heterodimers are efficiently delocalized, upon induction by -lactams, 
either by BlaR1 alone or in partnership with MecR1. This functional partnership would 
require an interaction between the activated BlaR1 and the N-terminal inducer domain 
of MecR1 (present in strains COL, VNG17 and RJP17 but not on strain HT0350), 
turning out the latter more efficient, in such a way that MecI dimers or MecI-BlaI 
hetero-dimers would delocalize easily from the operator region. However, no data in the 
literature provides any evidence to support this model and, data from strain HT0350, 
which has a virtual fully deleted mecR1, also refutes this hypothesis. Finally, but also 
against all published evidences, BlaR1 could act on MecI directly, inducing the mecA 
expression.  
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The MecI-BlaI heterodimer model may also explain the “enhancer” effect of 
pbla on the phenotypic expression of oxacillin resistance in the tested parental strains 
with low-level and heterogeneous oxacillin-resistance. Since those strains are mecI and 
bla negative, the constitutive expression of the truncated MecR1 may impose some 
fitness cost or toxic effect to the cell that interferes with the optimal phenotypic 
expression of resistance. This makes sense if one takes into account that truncated 
MecR1 (NTD-MecR1) has a complete N-terminal inducer domain with four 
transmembrane regions, and as such, overstated cellular amounts of this domain are 
likely to interfere with cell viability (107, 116). The introduction of the β-lactamase 
plasmid would bring a protective effect through the action of the repressor BlaI, since it 
is able to bind to the operator region of mecA and thus, control the production of both 
PBP2a and truncated MecR1. In the absence of β-lactams, BlaI would protect the cells 
from a cellular excess of NTD-MecR1, and in the presence of antibiotic mecA would be 
rapidly induced by the activated BlaR1, allowing the expression of high-level oxacillin-
resistance. Nevertheless, other factors are involved in the heterogeneous expression 
profile of oxacillin resistance, as strain COL with NTD-MecR1 is highly resistant and 
strain HT0350 virtually without MecR1 is low-level resistant.  
With these interesting but puzzling observations in our hands we aimed to 
clarify the mechanism underlying the effect of bla regulators on the expression of 
oxacillin resistance in MRSA strains. In order to do so, the subsequent step was to test 
the influence of each bla regulator or functional domain in the oxacillin-resistance 
phenotype. For this purpose, we constructed a series of recombinant plasmids 
containing, under the control of Pspac inducible promoter, the following inserts: blaI-
blaR1 with or without its operator sequences; blaR1 with or without its operator 
sequences and the N-terminal inducer domain of blaR1 with (NTD-blaR1) or without 
(∆NTD-blaR1) the zinc metalloprotease domain present in loop 3 (L3) (Fig. 10).  
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These recombinant plasmids were introduced into COL-I strain to evaluate the 
effect on the oxacillin-resistance phenotype. Unexpectedly, for all cases, using different 
concentrations of the inducer, it was not observed any increase of resistance levels as 
occurred in strain COL-I transformed with the intact β-lactamase plasmid. This result 
could be an indication that these genes might not be involved in the oxacillin-resistance 
expression. However, the phenotype revealed to be even more susceptible than COL-I 
strain, suggesting that the overexpression of the β-lactamase regulators might be toxic 
for the cell, as previously reported for MecR1 (107, 116). Although Pspac is an 
inducible promoter it presents a leaky activity, which together with the high-copy 
number of pSPT181 plasmid might account for this unexpected phenotype. To 
overcome this effect, we will co-transform these strains with a second plasmid 
overexpressing the repressor of Pspac promoter (112). 
We have also tested the phenotypic response of strain COL-I to the over-
expression of the cytoplasmic components of blaI-blaR1 system – blaI and the L3 
Fig 10 - Membrane topology of the penicillin-sensory transducer, BlaR1(56). 
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domain of blaR1.  The overexpression of blaI caused no significant alterations in the 
resistance phenotype: a slightly large halo could be noticed but the same effect was 
observed in the control experiment with the empty plasmid vector. Nevertheless, 
contrary to what was observed with blaR1, the blaI overexpression did not originate a 
hyper-sensitive phenotype, suggesting that this latter gene is not toxic to the cell. It is 
reasonable to assume that the overexpression of blaI alone would not reproduce the 
phenotype observed with the introduction of the complete bla plasmid, since the inducer 
is not present. Concerning the overexpression of L3 domain of BlaR1 in COL-I, no 
significant effect on the phenotypic expression of resistance was observed as well. 
BlaR1 has two functional domains, the sensor domain that extends to the extracellular 
medium where β-lactams can bind, and the transducer domain that lies in the cytoplasm 
and has four transmembrane α-helices interconnected by three loops (Fig. 10). 
Importantly, the zinc metalloprotease domain, present in loop 3 (L3), is cleaved during 
the induction process and is thought to be the connective element between BlaR1 and 
BlaI (57). Although no toxic effect was observed in these experiments, the lack of effect 
on COL-I phenotype suggests that the overexpressed L3 domain is not functional and 
that other parts of BlaR1 are required for its activation.  
In parallel with the above experiments, we set up a strategy to generate genetic 
knock-out’s of the bla regulator genes by allelic replacement with inducible counter-
selection, which allows a much rapid and efficient gene deletion in S. aureus than the 
traditional methods (7). As any genetic knock-out strategy, this strategy was designed 
for chromosomal (i.e single copy) genes. We found a MRSA clone fully characterized 
in a comparative genomic study (58) with a chromosomal cassette containing the -
lactamase locus. We have tested four prototype strains of this lineage but in all cases we 
could not succeed because the strains were resistant to bacteriophage infection or at 
least to the three phages routinely used for the genetic manipulation of S. aureus.  
Therefore, we decided to perform these experiments in strain COL-I with pbla and, as 
such, all steps required a “purifying” transduction step to assure that all copies of pbla 
were equal. These experiments are still in progress but eventually will clarify about the 
role of blaR1 and blaI on the phenotypic expression of oxacillin resistance.  
In summary, the results presented in this thesis demonstrate, doubtless, that the 
β-lactamase plasmid can increase the oxacillin-resistance phenotype in epidemic MRSA 
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strains, turning them from low-level and heterogeneous to high-level and homogeneous 
oxacillin-resistant strains; i.e. bla locus is a potent “enhancer” of the MRSA phenotype. 
Also, this work shows the contribution of the β-lactamase plasmid for a high level of 
oxacillin resistance in MRSA strains with either functional or non-functional mecI 
repressor; i.e. bla locus disrupts the mecA repression mediated by its cognate repressor. 
These are new and unexpected roles for the bla locus on the phenotypic expression of 
oxacillin resistance. Therefore, these results, contribute to the study of the regulation of 
mecA expression and point to a revision of the current model for the mecA regulation in 
clinical MRSA strains. Although we could not determine the exact mechanism 
underlying these observations, we have some evidences suggesting that bla regulators, 
blaI and blaR1, are involved. In fact, this is in perfect agreement with all evidence in the 
literature demonstrating that bla genes regulate efficiently mecA transcription and 
stabilize its acquisition. Hopefully, the experiments in progress will soon provide some 
insights into this important question. 
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ANNEX 
 
I – Culture Media, Reagents, Buffer Solutions and Antibiotics 
 
 
Medium
a 
Constituents (per Liter) 
Triptic soy agar (TSA) 
15.0 g Tryptone Peptone; 5.0 g Soytone 
Peptone; 5.0 g Sodium Chloride; 15.0 g 
Agar.  
Triptic soy broth (TSB) 15.0 g Tryptone Peptone; 5.0 g Soytone 
Peptone; 5.0 g Sodium Chloride. 
Brain heart infusion (BHI) 
200 g Calf Brains; 250 g Beef Heart; 10 g 
Peptone; 2 g Dextrose; 5 g Sodium 
Chloride; 2,5 g Disodium Phosphate. 
Luria-Bertani broth (LB) 10,0 g Tryptone; 5 g Yeast Extract; 10 g 
Sodium chloride. 
Luria-Bertani agar (LA) 10,0 g Tryptone; 5 g Yeast Extract; 10 g 
Sodium chloride; 15 g Agar. 
 
 
Buffer solutions
a 
Composition 
Tris-acetate-EDTA (TAE) 1X 40 mM Tris-acetate; 1 mM EDTA, pH 8,0. 
Stock solution: 50x 
Tris EDTA (TE) 1X 10 mM Tris pH 8,0; 1 mM EDTA, pH 8,0. 
 
 
 
 
a 
TSA, TSB and BHI were purchased from Difco; LA and LB were purchased from Roth. 
a 
Buffer solutions were prepared in house. 
Table 8 - Culture Media 
Table 9 - Buffer solutions 
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Enzymes
a 
Stock Solution 
Lysostaphin 10 µg/mL 
RNAse 10 µg/mL 
 
 
Transduction solutions
a 
Components (per Liter) 
Bottom phage agar 3 g casamino acids; 3 g yeast extract; 5,9 g 
NaCl; 12 g agar. 
Top phage agar 
3 g casamino acids; 3 g yeast extract; 5,9 g 
NaCl; 6 g agar. 
 
Bottom 0,3 GL agar 
3 g casamino acids; 3 g yeast extract; 5,9 g 
NaCl; 3,3 mL DL-lactic acid; 2 mL 
Glicerol 50%; 0,5 g Tri-sodium citrate; 
pH: 7,8; 6 g agar. 
 
Top 0,3 GL agar 
NaCl; 3,3 mL DL-lactic acid; 2 mL 
Glicerol 50%; 0,5 g Tri-sodium citrate; 
pH: 7,8; 12 g agar. 
 
Phage buffer 
 
1 Mm MgSO4; 4 Mm CaCl2; 50 mM 
TrisHCl pH: 7,8; 5,9 g NaCl; 1 g gelatin. 
CaCl2 Calcium (1x); Chloride (2x). 
a 
Transduction solutions were prepared in-house. 
a 
Lysostaphin was purchased from Ambi Products; RNAse was purchased from Quiagen. 
Table 10 – Media and solutions for transduction experiments 
Table 11 – Cell-wall lysis enzymes 
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Antibiotics
a 
Stock Solution 
Chloramphenicol 10 mg/mL 
Tetracycline 10 mg/mL 
Clavulanic acid 500 µg/mL 
Oxacillin 100 mg/mL 
Ampicillin 100  mg/mL 
Anidrotetracycline 100  µg/mL 
IPTG 1 M 
Penicillin 1000 U 
 
 
 
Restriction endonucleases
a 
Stock Solution 
BamHI 20,000 U/mL 
EcoR1 20,000 U/mL 
PstI 20,000 U/mL 
XmaI 10,000 U/mL 
NdeI 20,000 U/mL 
 
 
 
a 
Antibiotics were purchased from Sigma-Aldrich. 
a 
Restriction endonucleases were purchased from New England Biolabs. 
Table 12 – Antibiotic solutions 
Table 13 – Restriction endonucleases 
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II – PCR Primers, Reagents and Thermocycling Conditions 
 
 
 
 
 
 
Table 14 - Primers list 
Target 
Forward primer sequence
a 
5’  3’ (name/sequence) 
Reverse primer sequence
a 
5’  3’ (name/sequence) 
blaZ 
blaZ F1/ GATAAGAGATTTGCCTAT 
GC 
blaZ R1/ GCATATGTTATTGCTTG 
ACC 
blaR1 blaR1 F1/ CTTATGATTCCATGACA 
TACG 
blaR1 R1/ CATGACAATGAAGTA 
GAAGC 
blaZ-blaI-
blaR1 
blaF1/ ATTTTCTGTACACTCTCATC 
 
blaR1/ TTTTCGATTGATGAACAC CT 
NTDblaR1 
blaR1F2/ TATA CCCGGG GAACAT 
TTAATACGGAGTCC 
blaR10/ ATAT CCCGGG AAAGA 
AGGTGTTGAAATGG 
∆NTDblaR1 
blaR1F3/ TATA CCCGGG TTGGAG 
ATTGAATAGTCTCTGC 
blaR10/ ATAT CCCGGG AAAGA 
AGGTGTTGAAATGG 
blaR1L3 
blaL3F1/ TATA GAATTC TGGAGT 
TTAATATATGGAAAGCCTTATTATA
TCTTAAATA 
blaL3R1/ TATA GGATCC TTTGA 
CTGCTTTTTCAGATCG 
blaI 
blaF5/ TATA GGATCC ATTTTCTG 
TACACTCTCATC 
blaR9/ TATA CTGCAG ACATTTA 
TCAGATGGAAAGCC 
Upstream 
blaR1 
blaF6/ GGGGACAAGTTTGTACAA 
AAAGCAGGCTTTACACCTCGTTCGT
TAAGC 
blaR6/ TATA GGATCC ACATTTA 
TCAG ATGGAAAGCC 
Downstream 
blaR1 
blaF8/ CACA GGATCC GCATGTA 
ATTCA AACAGTTCACATGCC 
blaR7/ GGGGACCACTTTGTACA 
AGAGTGGGTTTTCGATTGATGAA 
CACC 
blaR1 knock 
out 
blaF9/ TTCATAACATCCCATTCA GC blaR8/ ATTGAAGCCTCAATAAGT GC 
mecA 
mecA P1/ AAATCGATGGTAAAGG 
TTGGC 
mecA P2/ AGTTCTGCAGTACCGG 
ATTTGC 
mecI 
mecI P4/ GCGGGTTTCAATTCACTT 
GTC 
mecI P5/ ATGGGAATTCAGCACA 
ACAAATTTCTGAGC 
a 
Underline segments represent recognition sites for restriction endonucleases. 
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GoTaq DNA Polymerase PCR 
 
 
 
 
 
 
 
 
 
 
 
Pfu Turbo DNA Polymerase PCR 
 
 
Reagent Volume (µL)
a 
Pfu buffer 10x 5 
Template 5 
dNTP’s 10 mM 4 
Forward primer 1 
Reverse primer 1 
Pfu Turbo polymerase 1 
H2O milliQ 33 
 
 
 
Reagent Volume (µL)
a 
Go Taq buffer 5x 5 
MgCl 25 Mm 1,5 
dNTP’s 10 mM  1 
Forward primer  0,5 
Reverse primer 0,5 
GoTaq polymerase 0,2 
Template 2 
H2O milliQ 14,3 
a
 for a final volume of 25 µL. 
a
 for a final volume of 50 µL. 
Table 15 - Routine PCR reaction mix 
 
Table 16 - High-fidelity PCR mix 
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Thermocycling conditions: 
 
 
Target Annealing temperature (ºC) Extension time (Minutes) 
blaZ 55 0,5 
blaR1 51 3,5 
blaZ-blaI-blaR1 51 3,5 
NTDblaR1 49 1 
∆NTDblaR1 55 1 
blaR1L3 55 0,5 
blaI 55 0,5 
Upstream blaR1 55 1 
Downstream blaR1 51 1 
blaR1 knock out 55 3 
mecA 55 1 
mecI 55 0,5 
 
 
 
 
 
 
 
 
 
 
Table 17 - Thermocycling conditions 
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III – bla Operon and Cloning Fragments 
 
 
Fig. 11 - bla operon and cloning fragments. Colorful arrows represent bla operon genes; black 
arrows represent cloning fragments. 
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IV – Summary of Experimental Phenotypic Data 
 
Strain Relevant genotype 
Oxacillin susceptibility 
Halo diameter
a
 
(mm) 
MIC 
(µg/mL)
b 
COL mecI
-
 ∆mecR1 bla- 8 > 800 
COL-I mecI ∆mecR1 bla- 32 0,75 
COL-I + pbla mecI ∆mecR1 blaZ blaI blaR1 7 > 800 
COL-I + blaIblaR1 mecI ∆mecR1 blaI blaR1 40 - 
COL-I+ OblaR1blaI mecI ∆mecR1 blaI blaR1 40 - 
COL-I + blaR1  mecI ∆mecR1 blaR1 41/19a - 
COL-I + OblaR1 mecI ∆mecR1 blaR1 39 - 
COL-I +  
NTDblaR1 
mecI ∆mecR1 ∆blaR1 40/23a - 
COL-I + 
∆NTDblaR1 
mecI ∆mecR1 ∆blaR1 44/21a - 
COL-I + blaR1L3 mecI ∆mecR1 ∆blaR1 32 - 
COL-I + blaI mecI ∆mecR1 blaI 37a - 
VNG17 mecI
-
 ∆mecR1 bla- 33/53a 6 
VNG17 + pbla mecI
-
 ∆mecR1 blaZ blaI blaR1 13 800 
VNG17-I mecI ∆mecR1 bla- 57 0,75 
VNG17-I + pbla mecI ∆mecR1 blaZ blaI blaR1 33/38a 1,5 
RJP17 mecI
-
 ∆mecR1 bla- 27/42a 1,5 
RJP17 + pbla mecI
-
 ∆mecR1 blaZ blaI blaR1 15 800 
    
Table 18 - Summary of experimental phenotypic data 
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Table 18 – Cont. 
Strain Relevant genotype 
Oxacillin susceptibility 
Halo diameter
a
 
(mm) 
MIC 
(µg/mL)
b 
RJP17-I + pbla mecI ∆mecR1 blaZ blaI blaR1 38/40a 1,5 
HT0350 mecI
-
 ∆mecR1 bla- 35 1,5 
HT0350 + pbla mecI
-
 ∆mecR1 blaZ blaI blaR1 16 800 
HT0350-I mecI ∆mecR1 bla- 56 0,75 
HT0350-I + pbla mecI ∆mecR1 blaZ blaI blaR1 40 3 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
a 
Heterogeneous population 
b 
MIC’s were determined based on PAP’s profile; first oxacillin concentration causing a three-log decrease 
of CFU’s (99,9 % of viability loss)  
